hepatitis C

Search with Google Search with Bing
Information
Disease name
hepatitis C
Disease ID
DOID:1883
Description
"A viral infectious disease that results_in inflammation located_in liver, has_material_basis_in Hepacivirus hominis, which is transmitted_by blood from an infected person enters the body of an uninfected person. The infection has_symptom fever, has_symptom fatigue, has_symptom loss of appetite, has_symptom nausea, has_symptom vomiting, has_symptom abdominal pain, has_symptom clay-colored bowel movements, has_symptom joint pain, and has_symptom jaundice." [url:http\://www.cdc.gov/hepatitis/HCV/index.htm, url:http\://www.cdc.gov/hepatitis/hcv/pdfs/hepcgeneralfactsheet.pdf, url:http\://www.cdc.gov/hepatitis/Resources/Professionals/PDFs/ABCTable.pdf]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
Genes Mutation Description Source Links
NCT ID Status Phase Summary Start date Completion date
NCT04677842 Active, not recruiting European Pregnancy and Paediatric Infections Cohort Collaboration: Paediatric Protocol January 1, 2013 January 1, 2025
NCT04710641 Active, not recruiting Phase 2 Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone January 1, 2022 May 1, 2025
NCT04652804 Active, not recruiting N/A Supporting Treatment Outcomes Among PWID January 21, 2021 December 31, 2024
NCT04026867 Active, not recruiting N/A The DETECT HCV Linkage to Care Trial November 20, 2019 July 2024
NCT06047275 Active, not recruiting HCV Microfluidic Diagnostics May 1, 2023 May 31, 2024
NCT04003454 Active, not recruiting N/A The DETECT HCV Screening Trial November 20, 2019 January 2024
NCT03949764 Active, not recruiting Phase 4 The Kentucky Viral Hepatitis Treatment Study September 23, 2019 December 31, 2024
NCT04947475 Active, not recruiting N/A Project MATLINK: Development and Evaluation of a Screening, Brief Intervention, & Referral to Treatment (SBIRT) Program for Opioid Dependent Prisoners and Probationers Transitioning to the Community January 1, 2017 July 31, 2024
NCT03819322 Active, not recruiting Phase 2 The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients August 15, 2019 March 17, 2025
NCT03809533 Active, not recruiting Phase 2 The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients May 29, 2019 May 1, 2024
NCT05668780 Active, not recruiting N/A Buprenorphine Integration Research and Community Health January 24, 2023 May 31, 2026
NCT03222531 Active, not recruiting Phase 2 Expanding the Pool in Orthotopic Heart Transplantation August 1, 2017 December 31, 2024
NCT03112044 Active, not recruiting Early Phase 1 Lung Transplant HCV, Pilot Study September 19, 2017 December 31, 2024
NCT02933970 Active, not recruiting N/A Comparison of Telemedicine to Usual Care for HCV Management for Methadone-maintained Individuals February 28, 2017 April 2024
NCT00015652 Completed N/A Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection March 2005
NCT00018031 Completed Phase 2 Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients June 2001 April 2009
NCT00021632 Completed Effects of Ribavirin on Zidovudine or Stavudine
NCT00029107 Completed Phase 2 Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis December 2001 May 2011
NCT00031343 Completed Phase 2 The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin February 2002 April 2004
NCT00037076 Completed Prevalence of Hepatitis C Virus Infection in HIV-Infected Children July 2003
NCT00038974 Completed Phase 3 Hepatitis C Antiviral Resistance in African-Americans August 2002 November 2005
NCT00039962 Completed Phase 3 Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin May 2002
NCT00040027 Completed Phase 3 Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin April 2002
NCT00047814 Completed Phase 2 Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection October 2002 March 2006
NCT00055341 Completed Phase 2 Treatment of Hepatitis C in Hemophilic Patients With HIV March 2002 June 2005
NCT00056862 Completed Phase 4 Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3 March 2003 June 2010
NCT00058903 Completed Phase 2 Treatment of Cholestatic Pruritus With Sertraline April 2003 March 2005
NCT00059358 Completed Phase 1/Phase 2 Zidovudine Levels in HIV Infected Patients Being Treated for HCV September 2001 June 2005
NCT00071916 Completed Racial Difference in HCV/Host Interactions March 2001
NCT00076427 Completed Leukapheresis for Research on HCV-Coinfected Patients January 14, 2004 June 9, 2015
NCT00078403 Completed Phase 2 Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV) July 2004 February 2009
NCT00085917 Completed Phase 2 Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients June 2004 November 2008
NCT00088504 Completed Phase 2 Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C July 2004 October 2006
NCT00096733 Completed Adult-to-Adult Living Donor Liver Transplantation Study October 2004 August 2010
NCT00097045 Completed Phase 2 Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis C November 2004 December 2006
NCT00097435 Completed Phase 2 A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C October 2004 August 2007
NCT00100581 Completed N/A Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults January 2007
NCT00108563 Completed Phase 4 VISN 20: Prophylactic Treatment of Interferon-Induced Depression in Hepatitis C Patients October 2003 September 2006
NCT00110799 Completed Phase 2 SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C April 2005 November 2006
NCT00117559 Completed N/A Improving Quality of Life for Veterans Undergoing Interferon Treatment July 2005 June 2008
NCT00124215 Completed Phase 1 Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection June 2005 February 2010
NCT00125762 Completed N/A FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy March 2005 October 1, 2008
NCT00128271 Completed Phase 1 Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection August 2005
NCT00132210 Completed Phase 4 Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients September 2002 June 2010
NCT00133276 Completed Phase 2/Phase 3 Prophylaxis of Psychiatric Symptoms During Anti-HCV Treatment August 2005 December 2009
NCT00135694 Completed Phase 2 Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant October 2005 September 2015
NCT00135798 Completed Phase 2 Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation September 2005 December 2009
NCT00136214 Completed Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects March 2004 March 2008
NCT00141284 Completed Phase 4 An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C October 2005 December 2006
NCT00148031 Completed Phase 4 Improving Hepatitis C Treatment in Injection Drug Users September 2003 March 2007
NCT00150904 Completed Peginterferon and Ribavirin on Virologic and Immunologic Parameters in Hepatitis C Mono- and Coinfected Patient (PRIVICOP) August 2005 January 2009
NCT00151580 Completed Phase 3 Treatment of Recurrent Hepatitis C After Liver Transplantation February 2002 July 2006
NCT00158522 Completed Phase 3 Efficacy of Pegylated Interferon Alone in Egyptian Patients With Acute Hepatitis C (ANRS 1213) February 2003 December 2007
NCT00163657 Completed Phase 4 Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection July 2002 January 2007
NCT00164372 Completed Phase 2/Phase 3 Behavioral Intervention for HIV and HCV-Uninfected Injection Drug Users May 2002 December 2006
NCT00916474 Completed Virology Follow up Study in Subjects Previously Treated With Telaprevir June 2009 December 2013
NCT00001117 Completed A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection
NCT00001712 Completed Frequency of Parenteral and Non-Parenteral Exposures to Blood Among Healthcare Workers at the Clinical Center, NIH and at Seven Academic Hospitals in Japan February 1998 October 2005
NCT00001982 Completed History of Hepatitis C in Volunteer Blood Donors June 1993 April 2000
NCT00004804 Completed Phase 3 Phase III Randomized Study of High Vs Standard Dose of Interferon Alfa for Chronic Hepatitis C August 1993
NCT00004846 Completed Nucleic Acid Amplification Testing (NAT) of Blood Donors for HCV and HIV December 1999 October 2002
NCT00004850 Completed Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection March 15, 1991
NCT00004851 Completed Generation of Anti-HCV Antibodies From Bone Marrow: Defining the Repertoire of Immune Response to HCV Quasispecies April 1999 May 2001
NCT00005657 Completed Genetics of Hepatitis C Virus Infection May 4, 2000 April 19, 2011
NCT00006301 Completed Immune Response to Hepatitis C Virus September 24, 2000 March 24, 2015
NCT00006643 Completed Comparing Single Photon Emission Computed Tomography (SPECT) and Liver Biopsy to Evaluate the Liver in Patients With HIV and Hepatitis C Virus
NCT00007709 Completed To Determine the Prevalence of HIV and Other Related Infections Such as Hepatitis C, Along With Associated Risk Behaviors, in Patients With Severe Mental Illness (SMI). January 1998
NCT00008463 Completed Phase 2 A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV) November 2000 August 2006
NCT00010816 Completed Phase 2 Herbal Treatment of Hepatitis C in Methadone Maintained Patients September 1998 June 2003
NCT01959321 Completed An Observational Study of Hepatitis C Virus in Pregnancy October 2012 June 30, 2021
NCT01962441 Completed Phase 3 SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection September 24, 2013 July 7, 2016
NCT01970904 Completed N/A Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients October 2013 March 2015
NCT01973049 Completed Phase 3 UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis December 2013 November 2014
NCT01979939 Completed Phase 3 UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects December 2013 November 2014
NCT01988753 Completed Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases October 2013 June 2016
NCT01995266 Completed Phase 3 Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual February 28, 2014 July 31, 2015
NCT02004379 Completed Register of Telaprevir and Boceprevir in Routine Clinical Practice November 2013 June 2015
NCT02022306 Completed Phase 1 TD-6450 SAD and MAD in Healthy Subjects February 2014 September 2014
NCT02032875 Completed Phase 3 Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant March 2014 January 2016
NCT02032888 Completed Phase 3 A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection. February 2014 January 2015
NCT02032901 Completed Phase 3 Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV January 2014 December 2014
NCT02044523 Completed Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound January 2014 June 2018
NCT02045693 Completed Phase 1 Drug Interaction & Methadone & Buprenorphine February 2014 April 2014
NCT02045966 Completed Phase 1 Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects February 2014 April 2014
NCT02053519 Completed Phase 3 Can Vitamin D Supplementation Improve Hepatitis C Cure Rates February 2014 October 2016
NCT02063607 Completed Phase 1 The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients December 2013 July 2016
NCT02064049 Completed Phase 4 Surveillance and Treatment of Prisoners With Hepatitis C October 2014 November 2019
NCT02068963 Completed Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing February 2014 December 2015
NCT02083367 Completed Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome January 2013 February 2015
NCT02084953 Completed Phase 1 Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects April 2014 May 2014
NCT02087111 Completed Phase 4 Telaprevir in Genotype 3 HCV April 2014 November 1, 2016
NCT02094443 Completed Phase 2 Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option March 2014 April 2015
NCT02095860 Completed Phase 1 Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325 April 2014 May 2014
NCT02098616 Completed N/A Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus July 2014 February 2016
NCT02103439 Completed Phase 3 An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients June 6, 2013 August 26, 2015
NCT02103569 Completed Phase 1 Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325 April 2014 July 2014
NCT02104843 Completed Phase 1 Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin April 2014 May 2014
NCT02108639 Completed Phase 1 To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet April 2014 June 2014
NCT02116179 Completed N/A DVD-based HIV/HCV Prevention Intervention for Drug-Involved Latino Criminal Justice Clients July 2014 May 2016
NCT02116543 Completed Phase 1 TD-6450 MAD Study in HCV Infected Subjects May 2014 November 2014
NCT02122094 Completed N/A Implementation of a Sexual Health Intervention for Young Men Who Have Sex With Men (MSM) in Two Vietnamese Cities May 2013 September 2016
NCT02123212 Completed N/A Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C February 2013 March 2014
NCT02133131 Completed Phase 2 Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074) June 13, 2014 February 1, 2016
NCT02139722 Completed N/A Patient-Centered Care and Asian Americans January 2, 2014 July 30, 2017
NCT02156570 Completed Phase 4 DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral) October 2014 December 2017
NCT02159352 Completed Phase 1 Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants June 2014 July 2014
NCT02161510 Completed Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Participants With Hepatitis C (MK-2248-002) July 2014 April 2015
NCT02175966 Completed Phase 2 Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study) July 28, 2014 December 17, 2015
NCT02203149 Completed Phase 2/Phase 3 Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058) August 1, 2014 May 16, 2016
NCT02214420 Completed Phase 4 SMV + SOF With/Without RBV for IFN-II Patients With CHC October 2014 June 2016
NCT02251990 Completed Phase 3 Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067) January 28, 2015 April 10, 2017
NCT02252016 Completed Phase 3 Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065) October 22, 2014 June 14, 2016
NCT02269059 Completed Phase 1 Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003) December 2014 April 2015
NCT02278419 Completed Phase 2 An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection December 2014 October 2015
NCT02294136 Completed N/A Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV Coinfection December 2013 April 28, 2017
NCT02304159 Completed Phase 4 Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics January 2015 August 2017
NCT02316184 Completed N/A Comparing Brief Alcohol Interventions For HIV-HCV Co-infected Persons January 2015 February 2022
NCT02319031 Completed Phase 3 Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis February 2015 December 2015
NCT02332707 Completed Phase 2 Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011) January 22, 2015 December 6, 2016
NCT02332720 Completed Phase 2 Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012) January 28, 2015 May 3, 2017
NCT02336139 Completed Phase 2 A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use March 16, 2016 November 28, 2018
NCT02347345 Completed Phase 4 Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs November 15, 2016 November 15, 2016
NCT02358044 Completed Phase 3 Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077) February 27, 2015 February 16, 2016
NCT02361541 Completed Determination of HCV Prevalence in a HIV Patient Cohort in Phnom Penh, Cambodia November 2014 April 2016
NCT02366286 Completed Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in African and Asian Immigrants November 2010 October 5, 2017
NCT02392494 Completed Phase 1 Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002) April 28, 2015 August 10, 2015
NCT02393365 Completed N/A Prevalence and Screening of Hepatitis C in Belgium in 2015 March 10, 2015 December 17, 2018
NCT02402699 Completed Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan December 15, 2015 March 23, 2017
NCT02404805 Completed N/A Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers February 2016 October 2016
NCT02405013 Completed Phase 2 Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa October 2015 November 2017
NCT02441283 Completed Phase 2/Phase 3 A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530 June 22, 2015 October 15, 2019
NCT02472925 Completed N/A Way to Cure HCV Adherence June 2015 December 2021
NCT02474043 Completed N/A A Community-based, Behavioral Intervention to Improve Screening for Hepatitis C Among High-risk Young Adults in Wisconsin August 2014 August 2016
NCT02483156 Completed Phase 2/Phase 3 Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Tablet Plus Ribavirin Tablet (Part A) Versus Single Dose (2 Tablets) of EHCV Containing Sofosbuvir, Ribavirin, and Natural Anti-hemolytic (B) in Egyptian Adults With Chronic Genotype 4 HCV Infection July 2015
NCT02496078 Completed Phase 3 A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection August 2015 February 2017
NCT02505243 Completed Evaluation of RIBAvirin Plasma COncentrations in Patients With Chronic Hepatitis C Infection Routinely Treated With Modern DAA Regimens June 2015 June 2016
NCT02515279 Completed An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria November 2008 December 2014
NCT02526641 Completed Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of Chronic Hepatitis C August 2015 November 2020
NCT02528461 Completed Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C January 2015 January 2020
NCT02531269 Completed Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period March 2015 February 2016
NCT02532907 Completed Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs August 2015 July 10, 2018
NCT02533934 Completed Phase 4 Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant August 2016 December 31, 2019
NCT02545400 Completed Quantification of Side Effects During Hepatitis C Therapy November 2013 June 2015
NCT02555475 Completed N/A The Prime Study - Comparing Hepatitis C Care and Treatment in a Primary Health Care Service With a Tertiary Hospital March 2016 May 22, 2018
NCT02562742 Completed Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection November 12, 2015 June 12, 2017
NCT02565862 Completed Phase 1 A Drug-drug Interaction Study Between Daclatasvir and Metformin January 2016 April 2016
NCT02565888 Completed Phase 1 A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat November 2015 January 2016
NCT02573376 Completed N/A Antiviral Pharmacology and Adherence in Drug Users November 2015 June 2021
NCT02574884 Completed N/A Identification of Viral Variants Involved in the Transmission of Hepatitis C and Characterization of Antigenic and Functional Properties of Their Envelope Glycoproteins August 2011 July 2013
NCT02580474 Completed Phase 4 The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure February 2016 April 2018
NCT02591277 Completed Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection November 30, 2015 November 1, 2017
NCT02596880 Completed Phase 3 Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics September 2015 June 2016
NCT02597790 Completed A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects October 2013 January 2020
NCT02600325 Completed Phase 3 Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV February 2016 January 11, 2019
NCT02601573 Completed Phase 2 Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083) January 5, 2016 January 6, 2017
NCT02601976 Completed Phase 4 Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population August 2010 September 2014
NCT02607735 Completed Phase 3 Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy November 11, 2015 June 21, 2017
NCT02607800 Completed Phase 3 Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy November 16, 2015 January 11, 2017
NCT02625909 Completed Phase 3 Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection. March 9, 2017 March 23, 2020
NCT02631772 Completed Phase 4 LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients June 1, 2016 June 30, 2018
NCT02641158 Completed N/A Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S. December 2015 May 9, 2018
NCT02647632 Completed Phase 2 Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir January 2016 April 2017
NCT02648022 Completed N/A Integrated Care for Patients With High Risk Substance Use and Psychiatric Disorder With Chronic Direct Acting Antiviral Treatment January 2012 February 2014
NCT02650024 Completed Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes January 2016 April 2021
NCT02652377 Completed Phase 1 EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients January 10, 2016 December 27, 2016
NCT02661126 Completed Phase 1 Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030) January 19, 2016 August 26, 2016
NCT02669966 Completed N/A Live Kidney Donors With Positive Anti-HCV Antibody, But Negative HCV PCR March 2016 February 2020
NCT02673489 Completed Phase 3 A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection March 15, 2016 May 26, 2017
NCT02683005 Completed Phase 1 Study of Hepatitis C Treatment During Pregnancy September 2016 February 3, 2020
NCT02705534 Completed Phase 3 Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1 September 2016 October 2017
NCT02706223 Completed N/A Testing and Treating Hepatitis C in Community Pharmacies December 2016 March 2019
NCT02718573 Completed Impact of Interferon-free Treatment for Hepatitis C Virus (HCV) on Blood Cells and Factors in Blood January 2015 December 11, 2017
NCT02727933 Completed Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea November 3, 2015 July 5, 2020
NCT02734173 Completed Phase 4 Pilot HCV Direct Acting Antiviral Therapy and Metabolism July 2015 May 31, 2017
NCT02740556 Completed N/A Evaluation of HepCure Toolkit to Improve Harvoni Adherence February 2016 March 31, 2019
NCT02749864 Completed Study to Evaluate the Prevalence of Hepatitis C in Spain in 2015 (PREVHEP) July 1, 2015 April 1, 2017
NCT02753699 Completed Phase 3 Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients December 2011 May 2015
NCT02755402 Completed N/A Accelerated Pre-treatment Evaluation for HCV Infected Persons Who Inject Drugs January 2017 May 2021
NCT02760758 Completed Phase 1 A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects April 2016 April 2017
NCT02768961 Completed Phase 4 Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C) May 10, 2016 May 10, 2017
NCT02772328 Completed N/A A Peer-based Mobile-health Intervention to Increase Access & Adherence to Hepatitis C Treatment & HIV Viral Suppression December 19, 2016 May 30, 2021
NCT02781649 Completed Phase 4 Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients July 20, 2016 January 1, 2018
NCT02782247 Completed Dynamic Liver Tests in Liver Disease May 2016 October 2022
NCT02785666 Completed Phase 3 Swiss HCVree Trial June 2016 August 2018
NCT02786758 Completed Eliminating Hepatitis C Transmission by Enhancing Care and Treatment Among HIV Co-infected Individuals April 2016 August 2019
NCT02795403 Completed N/A HCV Virions Bound Proteins January 2011 July 2015
NCT02824640 Completed N/A Patient-Centered Models of HCV Care for People Who Inject Drugs September 15, 2016 March 20, 2020
NCT02825212 Completed Phase 2/Phase 3 Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia February 2016 July 19, 2019
NCT02833298 Completed N/A Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening November 2016 April 1, 2018
NCT02836925 Completed Phase 2 Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection March 2016 November 2022
NCT02869776 Completed N/A Integrating HCV and HIV Screening During the Era of HIV Antigen Testing September 2016 July 26, 2017
NCT02877199 Completed Anti-E1E2 Antibodies (D32.10 Epitope-binding Antibodies) and HCV Triple Therapy June 2014 April 2015
NCT02881034 Completed Ribavirin Bioavailability After Telaprevir Exposure February 2014 February 2015
NCT02881762 Completed Phase 4 Maraviroc Efficacy for Hepatitis C June 1, 2017 March 27, 2019
NCT02902120 Completed Phase 4 HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant May 1, 2017 June 8, 2022
NCT02904252 Completed The Prevalence and Severity of HCV Infection in Thalassemia Major and Thalassemia Intermedia in Siriraj Hospital January 1, 2016 October 31, 2016
NCT02936648 Completed N/A Hepatitis C Testing in VA Community-Based Outpatient Clinics October 2015 September 2016
NCT02943330 Completed Depression, Genes, Cytokines, Chronic Fatigue, Physical Illnesses and Quality of Life August 2007 October 2010
NCT02970136 Completed N/A Increasing Uptake of Evidence-Based Screening Services Through CHW-led Multi-modality Intervention April 11, 2017 October 30, 2020
NCT02971488 Completed The Impact on Linkage-to-care of an Alternative Hepatitis C Screening Method in PWID January 15, 2017 May 10, 2019
NCT02992184 Completed PoC-HCV Genedrive Viral Detection Assay Validation Study September 2016 December 2016
NCT02992457 Completed Phase 4 Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection January 2015 December 2019
NCT03000023 Completed Anticipated and Perceived Benefits Following Hepatitis C Treatment October 2016 July 2018
NCT03004625 Completed Phase 3 Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV November 2016 April 2018
NCT03014986 Completed Current Treatment of HCV Infection After HSCT December 2015 July 2020
NCT03032666 Completed Phase 4 Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial May 1, 2017 August 6, 2018
NCT03038763 Completed Vertical Transmission of Hepatitis C in Adult Children of Female Baby Boomers May 11, 2017 June 30, 2019
NCT03057236 Completed N/A Pilot Feasibility Study of a Cognitive Behavioral Coping Skills (CBCS) Group Intervention for Hep C Therapy Patients March 1, 2014 December 31, 2014
NCT03071133 Completed Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy January 1, 2018 January 8, 2019
NCT03088995 Completed Pilot Study of HIV and Hepatitis B and C Screening in Surgery April 1, 2017 December 1, 2017
NCT03090035 Completed Phase 3 Impact of Interleukin 28B (rs12979860) Genotype on Virological Responses Chronic Hepatitis C Treatment January 1, 2014 December 31, 2014
NCT03092375 Completed Phase 3 Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects April 20, 2017 February 6, 2020
NCT03093415 Completed Phase 4 Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care May 30, 2017 June 6, 2019
NCT03109457 Completed Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma September 6, 2017 September 15, 2018
NCT03111966 Completed Effectiveness, Safety and Clinical Outcomes of Elbasvir/Grazoprevir: Results From a Spanish Real World Cohort March 31, 2017 November 30, 2017
NCT03118674 Completed Phase 2 Harvoni Treatment Porphyria Cutanea Tarda September 6, 2017 March 4, 2022
NCT03126370 Completed Phase 4 Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) January 8, 2018 October 1, 2019
NCT03127358 Completed N/A Smartphone Based aDOT Treatment With Fixed-Dose Elbasvir and Grazoprevir in PWIDs November 14, 2017 February 6, 2019
NCT03144440 Completed Real World Experience of Chronic Hepatitis C (CHC) Treatment in Israel December 13, 2016 January 1, 2021
NCT03145623 Completed Retrospective Efficacy and Safety Study With Elbasvir/Grazoprevir in HCV-infected Patients With Chronic Kidney Disease June 2, 2017 December 31, 2017
NCT03145844 Completed Direct Acting Agents in Hepatitis C Patients April 9, 2017 December 31, 2018
NCT03181074 Completed Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in Adults October 21, 2015 August 19, 2019
NCT03186235 Completed T Regulatory Cells in Hepatitis c Infected Patients July 1, 2018 August 1, 2019
NCT03186313 Completed Phase 3 A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection September 2016 November 30, 2017
NCT03195205 Completed Early Phase 1 Identification to Elimination in HCV-Infected Individuals June 1, 2017 April 20, 2020
NCT03197155 Completed Direct-acting Antivirals and Hepatocellular Carcinoma Recurrence June 1, 2016 March 31, 2017
NCT03200171 Completed Effect of DAAs on Behavior of HCC in HCV Patients February 10, 2018 July 19, 2021
NCT03200184 Completed Phase 4 Sofosbuvir and Daclatasvir in Treating Hepatitis C, A Study on 1000 Patients September 1, 2016 September 1, 2018
NCT03205618 Completed A Retrospective, Observational Study on the Effectiveness of Daclatasvir-Containing Regimens in Patients in KSA, UAE and Qatar April 26, 2016 June 27, 2017
NCT03214679 Completed N/A Accessible HCV Care Intervention for People Who Inject Illicit Drugs (PWID) July 20, 2017 June 30, 2021
NCT03219957 Completed Phase 1 Study of AT-527 in Healthy and HCV-Infected Subjects July 6, 2017 June 20, 2018
NCT03231930 Completed N/A Rapid Point-of-care Testing for Hepatitis C in Community Clinics (RAPID-EC) Pilot Study June 29, 2017 May 17, 2018
NCT03235154 Completed Phase 4 A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic October 11, 2017 September 26, 2019
NCT03236506 Completed Phase 2 A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study January 19, 2018 October 28, 2020
NCT03242655 Completed N/A HCV Group Evaluation and Treatment Uptake (HCV GET-UP) Intervention February 21, 2017 October 30, 2020
NCT03245931 Completed Hepatitis C Education for Pregnant Women With Opiate Addiction - Phase 1 July 20, 2017 August 26, 2019
NCT03249194 Completed Early Phase 1 Hepatitis C Virus Donor Positive Kidney Transplantation for Hepatitis C Virus Negative Recipients August 17, 2017 March 15, 2020
NCT03252483 Completed N/A Integrating HIV and Hepatitis C Screening in an Urban Emergency Department December 2012 May 2013
NCT03254121 Completed Genome Studies of Hepatocellular Carcinoma Developed in Hepatitis C Patients With Sustained Virological Response January 1, 2017 September 1, 2020
NCT03290755 Completed Sexual Hepatitis C in HIV Positive Men Who Have Sex With Men (MSM) in Bordeaux November 8, 2017 March 13, 2018
NCT03293576 Completed N/A A Self-efficAcy Intervention to reDuce Injecting Risk behAviour and hePatitis c reinfecTion Rates February 22, 2018 January 3, 2020
NCT03303599 Completed Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6 November 13, 2017 January 24, 2020
NCT03316313 Completed Hepatitis C Screening in the Primary Care Setting June 2016 April 2017
NCT03318887 Completed Impact of Sofosbuvir and Daclatasvir Concentration on HCV RNA February 1, 2014 June 30, 2015
NCT03320889 Completed N/A Hepatitis C Education for Pregnant Women With Opiate Dependence - Phase 2 October 30, 2017 August 26, 2019
NCT03324633 Completed Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV June 2005 December 2022
NCT03341988 Completed Phase 1 Evaluation of Treatment of Chronic HCV Patients in Chronic Kidney Disease Versus End Stage Renal Disease Patients November 22, 2017 May 1, 2018
NCT03362476 Completed N/A Computer-based Intervention for Alcohol-using HIV/HCV+ Women January 3, 2018 February 28, 2022
NCT03365635 Completed Phase 4 Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C September 22, 2019 September 1, 2020
NCT03366610 Completed Study to Assess Clinical Outcomes in Chronic Hepatitis C Patients Previously Treated With Daclatasvir-Based Regimens April 28, 2017 April 30, 2019
NCT03377478 Completed Phase 1 Expanding the Pool in Lung Transplantation July 30, 2019 April 1, 2022
NCT03401697 Completed Eliminating Hepatitis C Virus January 23, 2018 March 1, 2021
NCT03402334 Completed N/A Counseling Hepatitis C Virus (HCV) Positive Patients for Cardiovascular Disease Risk Factors March 11, 2019 April 30, 2021
NCT03413696 Completed Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients September 8, 2017 December 31, 2019
NCT03415009 Completed Prevalence of IL28B Polymorphism in Hepatitis C Patients June 2014 December 2016
NCT03420300 Completed Phase 4 EBR/GZR for HCV-1b Patients Receiving Hemodialysis June 5, 2018 February 3, 2020
NCT03426787 Completed N/A Helping Empower Liver and Kidney Patients September 26, 2017 July 30, 2019
NCT03447210 Completed N/A Study of HIV, HCV, APS and Phylogenetics for PWID February 26, 2018 February 28, 2022
NCT03468673 Completed International Validation of a Sexual Quality of Life Questionnaire Specific to HIV and Hepatitis C (PROQOL-SexLife) February 20, 2015 June 30, 2020
NCT03482388 Completed N/A Crowdsourcing to Promote HBV and HCV Testing in China May 9, 2018 June 9, 2018
NCT03483818 Completed N/A Pilot Trial of Directly Observed Anti HCV Therapy & Contingency Management in a Population on Opiate Substitute Therapy November 2015 November 2016
NCT03492112 Completed N/A A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams September 10, 2019 November 30, 2021
NCT03512210 Completed Phase 4 Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection October 22, 2018 February 28, 2021
NCT03513393 Completed Phase 1 Influence of Cola on the Absorption of the HCV Agent Velpatasvir in Combination With PPI Omeprazole. August 1, 2018 December 1, 2018
NCT03523871 Completed Phase 2 A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret May 12, 2018 September 1, 2020
NCT03526939 Completed DRug Use and Infections in Hai Phong ViEtnam Among Persons Who Inject Drugs October 17, 2016 January 10, 2020
NCT03537196 Completed Phase 4 DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C) November 13, 2018 December 30, 2022
NCT03537274 Completed Phase 2/Phase 3 Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016) August 5, 1997 July 23, 1999
NCT03564639 Completed Examining Hepatitis C Reinfection Rates in Kenya October 1, 2019 February 1, 2021
NCT03566563 Completed Epidemiology of Chronic Hepatitis C and Disease Modelling February 21, 2017 May 29, 2020
NCT03570112 Completed Transmission of Chronic Hepatitis C in Pregnancy June 8, 2018 February 27, 2023
NCT03579576 Completed Simplified Antiviral Treatment Strategy for Hepatitis C in Myanmar December 20, 2017 June 30, 2019
NCT03581383 Completed N/A Community Access, Retention in Care, and Engagement for Hepatitis C Treatment August 21, 2018 December 31, 2022
NCT03587714 Completed Prevalence of Hepatitis c Virus Infection Among Rheumatological Patients January 1, 2017 March 1, 2018
NCT03595527 Completed N/A Universal HIV Screening and Targeted HCV Screening in Emergency Department July 10, 2018 October 10, 2020
NCT03603327 Completed N/A Response Guided Treatment With Direct Acting Anti-Viral Medications for Chronic HCV Infection February 25, 2018 December 31, 2020
NCT03619837 Completed Phase 4 Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant July 15, 2018 August 13, 2020
NCT03620474 Completed Phase 1/Phase 2 Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis July 24, 2018 February 28, 2022
NCT03627299 Completed Phase 4 Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors September 25, 2018 September 20, 2021
NCT03627546 Completed N/A HCV Seek, Test and Rapid Treatment for Young PWID September 18, 2018 June 30, 2021
NCT03652675 Completed N/A Understanding and Intervening With Heavy Drinking Among Patients With HIV and HCV November 1, 2018 June 8, 2020
NCT03654365 Completed N/A Advanced Electronic Population Health and Personal Health Record Tools to Improve Once Lifetime Hepatitis C Screening November 17, 2016 March 25, 2017
NCT03669835 Completed N/A The Sublimated Mare Milk Supplement in Hepatitis C March 28, 2018 December 1, 2020
NCT03670251 Completed N/A Evaluation of Hepatitis C Viral Load Quantification on DBS in Vietnam May 9, 2019 July 11, 2019
NCT03686722 Completed Phase 1 Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin September 9, 2017 December 6, 2017
NCT03688061 Completed Phase 1 Class II Invariant Chain HCV Vaccine Study December 4, 2017 August 4, 2022
NCT03697135 Completed Ask a Friend to Take a Test for Hepatitis C Infection September 1, 2018 December 30, 2019
NCT03702998 Completed Hepatocellular Carcinoma in HIV-infected Individuals in Asian Population December 1, 2018 January 16, 2023
NCT03706742 Completed N/A STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention September 10, 2018 March 31, 2021
NCT03707080 Completed Direct Acting Antiviral-Post Authorization Safety Study March 9, 2018 June 30, 2021
NCT03712553 Completed N/A Behavioral Science and Hepatitis C Screening Outreach March 15, 2019 October 15, 2020
NCT03740230 Completed An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs September 26, 2018 July 21, 2023
NCT03781726 Completed Phase 4 Multi-center Study to Transplant Hepatitis-C Infected Kidneys April 10, 2019 December 31, 2021
NCT03801707 Completed Phase 2/Phase 3 Utilization of Hepatitis C Positive Kidneys in Negative Recipients March 22, 2019 April 30, 2021
NCT03803410 Completed Surveillance of HCV in Uremics and Linking to Medical Care January 7, 2019 May 20, 2022
NCT03817619 Completed Phase 1 Bioequivalence Study of Crushed Elbasvir/Grazoprevir Compared to the Whole Tablet March 28, 2019 July 30, 2019
NCT03818308 Completed Phase 2 Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir May 28, 2019 June 8, 2021
NCT03823911 Completed Phase 4 Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication November 18, 2018 December 31, 2022
NCT03831555 Completed N/A Tool to Improve Treatment Adherence and Outcomes at Grady Liver Clinic June 5, 2017 June 30, 2018
NCT03833362 Completed Phase 3 Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study) May 7, 2014 February 21, 2017
NCT03883698 Completed Phase 3 Safety of Sofosbuvir in People With Advanced Kidney Failure March 15, 2019 August 1, 2020
NCT03898349 Completed N/A eHealth Partnered Evaluation Initiative - Evaluation of the Initial Deployment of VA's Annie Texting System October 1, 2015 September 30, 2017
NCT03902366 Completed HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function May 16, 2019 December 29, 2023
NCT03908294 Completed Change of Glucose Metabolism and Fibrosis Markers in Patients With Hepatitis C Under Treatment With Antiviral Agents August 13, 2018 April 1, 2020
NCT03923595 Completed Puglia HCV Micro-elimination Program July 30, 2019 January 31, 2021
NCT03935906 Completed N/A Reaching mEthadone Users Attending Community pHarmacies With HCV October 8, 2019 January 14, 2021
NCT03939013 Completed N/A Hepatitis C: Community Testing and Treatment (CT2 Study Myanmar) January 30, 2019 December 20, 2020
NCT03961828 Completed Phase 4 Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus October 1, 2017 March 1, 2019
NCT03980301 Completed Screening Hepatitis Positive Women for Congenital Anomalies October 11, 2018 October 20, 2020
NCT04019717 Completed Phase 2 Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection June 20, 2019 March 23, 2020
NCT04033887 Completed Evaluation Study of RDTs Detecting Antibodies Against HCV September 21, 2018 March 15, 2019
NCT04036396 Completed N/A Prevention Support for People Leaving Jail November 14, 2019 March 31, 2024
NCT04036760 Completed Implementation and Evaluation of Care Coordination in Linkage to Care for Hepatitis C Following Release From New York City Jails May 2015 December 14, 2017
NCT04047680 Completed eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs February 2015 June 2019
NCT04090164 Completed Association of Hepatitis C Virus With Breast Cancer September 1, 2019 June 1, 2020
NCT04113629 Completed N/A Simplified Monitoring Myanmar SM2 Study January 22, 2019 December 22, 2020
NCT04137094 Completed N/A Development and Pilot Testing of a PHCI for Emergency Department Patients Who Decline Rapid HIV/ HCV Screening October 16, 2019 January 1, 2021
NCT04159545 Completed Future Destinations: Journeys Towards Citizenship December 15, 2019 May 31, 2023
NCT04204447 Completed N/A Hepatitis C-Video vs. Brochure Education Delivery November 27, 2019 October 31, 2020
NCT04220645 Completed N/A Opportunstic Hepatitis C Virus Treatment October 1, 2019 June 30, 2022
NCT04236973 Completed N/A Truenat™ HCV RNA Assay Evaluation January 12, 2020 July 20, 2021
NCT04268173 Completed Phase 3 Community-Based, Client-Centered Prevention Homes to Address the Rural Opioid Epidemic- Aim 3 March 12, 2020 July 31, 2023
NCT04314414 Completed N/A Coaching for HCV and HIV December 20, 2020 January 28, 2022
NCT04363411 Completed N/A Reaching Out to the UNdiagnosed People Infected With Blood Borne Viral Infections October 25, 2018 October 22, 2019
NCT04366492 Completed N/A HBV/HCV/HIV in Belgian Prisons April 1, 2019 March 31, 2020
NCT04389268 Completed P300 in Early Cognitive Impairment in Hepatitis C Virus February 1, 2018 February 1, 2019
NCT04427202 Completed N/A Ending Transmission of HIV, HCV, and STDs and Overdose in Rural Communities of People Who Inject Drugs (ETHIC) August 14, 2020 August 16, 2023
NCT04437277 Completed N/A Screening for Chronic Hepatitis C Virus in Hospitalized Patients November 22, 2019 November 30, 2021
NCT04457050 Completed Phase 4 Effect of Hepatitis C Clearance on Insulin Resistance October 30, 2017 December 30, 2019
NCT04515797 Completed Phase 4 QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir May 1, 2021 August 31, 2023
NCT04525690 Completed N/A Improving Inpatient Screening for Hepatitis C September 21, 2020 April 10, 2021
NCT04540081 Completed N/A Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer October 5, 2020 October 5, 2022
NCT04575896 Completed Phase 4 Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors November 20, 2020 December 1, 2023
NCT04596475 Completed Phase 1/Phase 2 Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor May 28, 2021 April 21, 2022
NCT04600479 Completed N/A Study on the Prevalence of Hepatitis C In a psychiatRic Population November 26, 2020 March 24, 2023
NCT04653818 Completed Phase 4 HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial October 5, 2020 October 24, 2022
NCT04698629 Completed Hepatitis C Pharmacy-based Strategy for Injectors November 5, 2020 June 30, 2023
NCT04719338 Completed N/A Occult HCV Infection After DAAD Treatment in Haemodialysis Patients March 1, 2021 October 1, 2021
NCT04741750 Completed N/A Increasing HCV Linkage to Care Among People Who Inject Drugs February 2, 2021 September 30, 2023
NCT04798521 Completed N/A TeleHepC Treatment Trial June 30, 2020 January 10, 2024
NCT04809246 Completed N/A Prisons Evaluation of a One-stop-shop InterVentiOn October 31, 2019 September 10, 2021
NCT04812990 Completed A Cross Sectional Observational Study on Relation Between Oral Manifestation and Hepatitis C in Egypt March 1, 2021 August 1, 2021
NCT04853394 Completed N/A Tajik Migrant Health Education Study October 19, 2021 May 28, 2023
NCT04873609 Completed N/A Electronic Record Assimilation and Subsequent Eradication of Hepatitis C May 1, 2019 April 30, 2020
NCT05002907 Completed Epidemiology of Hepatitis B, C and D and HIV Along the Maroni River Bordering French Guiana and Suriname (MaHeVi) January 1, 2018 December 23, 2019
NCT05108935 Completed N/A Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP February 17, 2022 March 30, 2023
NCT05127187 Completed Estimation of the Prevalence of HIV, Hepatitis C and Hepatitis B Infection Among Detainees in the Nîmes Administrative Detention Center February 8, 2022 December 7, 2022
NCT05264558 Completed Phase 4 Preparing for the Final Phase of Hepatitis C Elimination. Cairns Final 30% July 25, 2022 September 30, 2023
NCT05270135 Completed N/A ASAP: Access to Syringes at Pharmacies for the Prevention of Bloodborne Infections Among People Who Inject Drugs December 1, 2022 September 30, 2023
NCT05369507 Completed N/A Eliminating HCV in Rural South Carolina Utilizing NP Led Mobile Clinics and Virtual Care Coordination September 1, 2021 September 16, 2023
NCT05412017 Completed N/A EPIC: Evaluation of Pharmacy-based Identification and Treatment of HCV July 13, 2020 July 30, 2023
NCT05449847 Completed Plasma MicroRNA for Prediction of Hepatocellular Carcinoma May 13, 2021 March 20, 2022
NCT05465434 Completed Phase 3 Study to Evaluate the Possible Antifibrotic Effect of Zinc Sulphate in Chronic HCV Patient Receiving Direct Acting Anti-viral Therapy. August 1, 2022 August 30, 2023
NCT05466981 Completed N/A HCV-Smoking Cessation Study November 23, 2020 November 11, 2021
NCT05472051 Completed Health and Migration Trajectories of Housekeepers in Bamako February 28, 2022 June 22, 2023
NCT05498779 Completed Ablation of Hepatocellular Carcinoma: a Nationwide Study June 1, 2022 September 1, 2023
NCT05710120 Completed Hepatitis C Screening Alerts January 16, 2023 October 17, 2023
NCT05725109 Completed Hepatitis C Diagnosis to Treatment Management January 16, 2023 October 17, 2023
NCT06357819 Completed INSTI® HCV (Hepatitis C Virus) Antibody Self-Test Contrived Result Interpretation October 12, 2023 December 17, 2023
NCT00192569 Completed Phase 4 Australian Trial in Acute Hepatitis C July 2004 June 2010
NCT00203606 Completed Phase 4 Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past Intravenous Drug Users Infected With Hepatitis C January 2004 August 2011
NCT00205075 Completed Impact of Moderate Alcohol Use on Hepatitis C Virus (HCV) Progression August 2004 June 2008
NCT00207311 Completed Phase 4 Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus August 2005 May 2009
NCT00207363 Completed Phase 4 Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC February 2002 January 2010
NCT00207402 Completed Phase 4 Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin October 2005 July 2010
NCT00209118 Completed N/A Paroxetine for the Treatment of Interferon Related Side Effects for Hepatitis C July 2005
NCT00211848 Completed Phase 2 Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers June 2000 December 2005
NCT00218556 Completed N/A Preventing Depression in Methadone Maintenance Patients Receiving Hepatitis C Treatment - 1 January 2004 June 2008
NCT00229580 Completed Phase 1 Health Behavior Feedback Study for Veterans With Hepatitis C December 2003 January 2006
NCT00237432 Completed Study of the Immune Response to Hepatitis C Virus April 2003 February 2008
NCT00239252 Completed Phase 3 Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C
NCT00241618 Completed Phase 4 Timing and Duration of Acute Hepatitis C Treatment January 2002 January 2006
NCT00241917 Completed N/A A Video-Based HCV Curriculum for Drug Users November 2005 May 2007
NCT00241943 Completed N/A A Video-Based HCV Curriculum for Active Injection Drug Users November 2005 August 2007
NCT00244374 Completed N/A A Randomized Trial of Vaccine Adherence in Young Injection Drug Users August 2004 June 2008
NCT00246363 Completed Phase 1/Phase 2 A Clinical Research Study Designed To Determine If Treatment of Hepatitis C With Milk Thistle is More Effective Than No Treatment In Patients Infected With Both HIV And Hepatitis C January 2005 December 2007
NCT00248339 Completed Phase 3 Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection May 2002 July 2005
NCT00249574 Completed N/A Bridging Active Heroin Users to Hepatitis C Treatment Using Buprenorphine - 1 June 2003 June 2006
NCT00249860 Completed Phase 3 A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects September 2002 August 2005
NCT00251199 Completed Phase 1 VX-950 and Peginterferon for Hepatitis C October 2005 March 2006
NCT00252642 Completed N/A Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C November 2005 September 2007
NCT00262483 Completed Phase 2 Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C December 2005 April 2006
NCT00266318 Completed Phase 4 Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy December 2005 May 2007
NCT00275548 Completed Phase 4 Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C July 2004 April 2009
NCT00277862 Completed Phase 4 Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4 April 2002 April 2007
NCT00295607 Completed Phase 2 Comparing Efficacy and Safety of Tacrolimus With Steroids or Monoclonal Anti-IL2R Antibody in Hepatitis C Virus (HCV) Positive Liver Transplant Patients June 2005 June 2008
NCT00310336 Completed Phase 2/Phase 3 Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine August 2006 September 2009
NCT00314054 Completed Phase 1 Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults May 2006 October 2007
NCT00315432 Completed Phase 2 NATURAL HISTORY-Hepatitis C Virus/ Human Immunodeficiency Virus Coinfection September 2000 November 2003
NCT00317746 Completed Phase 3 Trial of Citalopram for the Prevention of Depression November 2006 March 2012
NCT00324389 Completed Phase 2 Interferon-Induced Gene Expression in Liver Cells and Peripheral Blood Lymphocytes May 2006 June 2006
NCT00328042 Completed N/A Hepatitis C Self-Management May 2007 August 2010
NCT00328549 Completed Phase 2 A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV) October 2001 December 2002
NCT00333710 Completed N/A Evaluating a Telehealth Treatment for Veterans With Hepatitis C and PTSD September 2006 October 2009
NCT00343525 Completed Phase 1 Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C May 2006
NCT00348660 Completed Screening for Hepatitis C During Pregnancy at a Toronto Inner City Prenatal Clinic August 2005 October 2010
NCT00363259 Completed Phase 3 Pegintron Induction Therapy in HCV Non-Responders July 2002 November 2005
NCT00367887 Completed Phase 2 A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects October 2006 July 2008
NCT00368225 Completed Transplant-Related Accelerated Progression of Hepatitis C June 22, 2006 January 22, 2009
NCT00372983 Completed Phase 1 Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard Therapy August 2006 December 2007
NCT00381953 Completed Phase 3 High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV February 2003 July 2006
NCT00381992 Completed Risk Assessment of Long-Haul Truck Drivers September 2005 March 2010
NCT00383864 Completed Phase 4 Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation. July 2001 March 2006
NCT00389376 Completed Phase 1 Phase I Trial of Silymarin for Chronic Liver Diseases November 2006 February 2008
NCT00391482 Completed Phase 2/Phase 3 Study to Reduce Intravenous Exposures (STRIVE) June 2002 February 2005
NCT00393276 Completed Phase 1 Determining Responses to Two Different Vaccines in HIV and HCV Infected Individuals August 2007 July 2009
NCT00401336 Completed N/A Quantification of Liver Iron Overload and Steatosis Using Magnetic Resonance Imaging November 2006 March 2013
NCT00403533 Completed Phase 2 Assessment of the Antiviral Effect of Atorvastatin on Hepatitis C Virus February 2006 July 2006
NCT00407732 Completed N/A Overcoming Psychiatric Barriers to the Treatment of Hepatitis C January 2007 October 2011
NCT00420784 Completed Phase 2 A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3) February 2007 April 2009
NCT00422838 Completed Study Investigating Immunological Effects of Treatment for Chronic Hepatitis C Patients. January 2007 November 2010
NCT00435201 Completed Characterization of Clonal B Cell Populations in HCV Infection January 2007 June 2013
NCT00441493 Completed N/A Fluvastatin Versus Hepatitis C Virus September 2006 September 2007
NCT00444002 Completed Oxidative Stress and Fatty Acids in Hepatitis C July 2005 July 2010
NCT00445315 Completed Phase 1 A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients January 2007 June 2008
NCT00446940 Completed Phase 2 Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C December 2006 March 2007
NCT00466219 Completed Phase 3 Ribavirin/Pegasys Treatment of Recurrent Hepatitis C After Liver Transplant May 2002 December 2006
NCT00469131 Completed Phase 3 Effects of Immunosuppression on HCV Recurrence After Living Donor Liver Transplantation - Comparative Study Between Tacrolimus + MMF and Tacrolimus + Steroid September 2003 August 2011
NCT00470210 Completed Phase 4 Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens May 2007 June 2009
NCT00484328 Completed Phase 4 Ribavirin, Its Dosing Regime July 2007 December 2012
NCT00494936 Completed Effects of HIV and Hepatitis C Virus on the Brain May 2006 July 2009
NCT00500747 Completed Phase 1 Chiron Corp HCV E1/E2 Vaccine August 2003 August 2005
NCT00502099 Completed Phase 4 Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4 January 2006 May 2009
NCT00502788 Completed Phase 2 Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study) May 2003 August 2006
NCT00502970 Completed Phase 4 Short Course of Interferon Treatment in Patients With HCV Infection May 2004 November 2007
NCT00512278 Completed Phase 2 Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C July 2007 May 2012
NCT00518622 Completed Phase 1 Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED) July 2007 September 2008
NCT00527540 Completed Phase 3 Effectiveness and Side Effects of Pegylated Interferon Alpha-2a (Pegaferon®) Plus Ribavirin in the Patients With Chronic Hepatitis C February 2007 December 2008
NCT00527774 Completed Effect of HCV Infection on Insulin Resistance and Malnutrition-inflammation Complex Syndrome in Regular Hemodialysis Patients September 2007 March 2008
NCT00535847 Completed Phase 2 A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy October 2007 February 2010
NCT00538811 Completed Phase 2/Phase 3 Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Non-responders
NCT00545558 Completed Phase 1 Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV April 2006 March 2012
NCT00560690 Completed Phase 4 The Effect of Adding Metformin to the Treatment of Hepatitis C December 2007 December 2010
NCT00562783 Completed Phase 2 A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis January 2005 May 2006
NCT00564811 Completed N/A Effect of Agaricus Blazei (Murrill) ss. Heinemann (Sun Mushroom) March 2003 September 2004
NCT00580801 Completed Phase 2 An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection January 2008 January 2010
NCT00590564 Completed Phase 2 SHO-SAIKO-TO for Patients With Chronic Hepatitis C: A Phase II Study October 2002 February 2011
NCT00593151 Completed Phase 1/Phase 2 Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C January 2008 March 2009
NCT00596843 Completed Phase 3 Chronic Hepatitis Intervention Project for Drug Users September 2003 November 2006
NCT00598416 Completed N/A Psychoeducation for Hepatitis and Alcohol Behaviors September 2006 August 2013
NCT00612755 Completed Phase 4 Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4 October 2005 January 2008
NCT00621296 Completed Phase 2 Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C January 2008 February 2009
NCT00627926 Completed Phase 3 A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV) March 2008 May 2010
NCT00630058 Completed Phase 1 A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C April 2008 March 2009
NCT00633243 Completed N/A Effective Treatment of Hepatitis C in Substance Users April 2007 September 2011
NCT00635804 Completed Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002) February 19, 2008 December 22, 2009
NCT00643695 Completed N/A Efficacy of an Exercise Intervention to Decrease Depressive Symptoms in Veterans With Hepatitis C March 2008 October 2014
NCT00657397 Completed Phase 3 Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices January 2009 December 2011
NCT00674492 Completed Hepatitis C Virus (HCV) Treatment Completion or Withdrawal May 2008 August 2008
NCT00684268 Completed Phase 2 Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders October 2007 June 2011
NCT00686517 Completed Phase 3 Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137) December 2003 December 2010
NCT00688012 Completed Phase 1 Safety Study of SPC3649 in Healthy Men May 2008 May 2009
NCT00703469 Completed Phase 1 A Study of MDX-1106 to Treat Patients With Hepatitis C Infection October 2008 October 2009
NCT00703560 Completed Study of Hepatitis C Virus (HCV) Viral Kinetics in HIV/HCV and HCV Patients September 2005 January 2013
NCT00704184 Completed Phase 2 Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007) July 25, 2008 April 14, 2010
NCT00704717 Completed Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301) September 2005 December 2007
NCT00704964 Completed Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413) May 2005 October 2009
NCT00707603 Completed Chronic Hepatitis C and Insulin Resistance May 2006 December 2008
NCT00707772 Completed Phase 4 Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection March 2007 September 2009
NCT00707850 Completed Phase 4 Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection May 2007 September 2009
NCT00709228 Completed Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793) May 2006 November 2008
NCT00720434 Completed Phase 2 A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection August 2008 March 2010
NCT00722423 Completed N/A An Integrated Care Model for Improving Hepatitis C Virus Patient Outcomes May 2009 May 2014
NCT00723632 Completed Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED) September 2005 December 2010
NCT00724230 Completed Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED) February 2006 December 2008
NCT00724295 Completed Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505) April 2005 December 2008
NCT00724451 Completed Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1) July 2008 October 2011
NCT00724464 Completed Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209) December 2007 October 2010
NCT00724854 Completed Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427) August 2006 September 2009
NCT00724893 Completed Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423) August 2005 August 2012
NCT00725205 Completed Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690) March 2006 October 2010
NCT00727311 Completed Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED) August 2005 June 2009
NCT00728494 Completed Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671) October 2005 December 2007
NCT00728936 Completed Phase 1 Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients September 2007 May 2010
NCT00730431 Completed Phase 1 Single-Dose Escalation Study of IDX184 in Healthy Volunteers (MK-2355-002) July 2008 October 2008
NCT00736242 Completed Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584) December 2005 December 2011
NCT00741169 Completed Phase 1 TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing. June 2008 December 2008
NCT00747539 Completed Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy July 2008 June 2015
NCT00752648 Completed Phase 1 TMC435350-TiDP16-C106: A Phase I Trial to Compare the Bioavailability and Plasma Pharmacokinetics After a Single Oral Dose of TMC435350 of 2 Different Solid Formulations Relative to a Powder Blend Capsule July 2008 January 2009
NCT00752687 Completed Phase 1 A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults September 2008
NCT00755742 Completed N/A Lifestyle Intervention Targetting Obesity and Insulin Resistance in Chronic Hepatitis C November 2008 August 2011
NCT00758043 Completed Phase 3 A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response October 2008 July 2010
NCT00775125 Completed Phase 1 VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state. June 2008 October 2008
NCT00780416 Completed Phase 3 Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C November 2008 August 2010
NCT00781274 Completed Phase 3 Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy December 2008 July 2010
NCT00781976 Completed Phase 1 Antiviral Activity of AZD7295 in HCV Carriers November 2008 March 2010
NCT00787371 Completed Phase 2 Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED) June 2005 July 2006
NCT00794391 Completed N/A Effects of Motivational Interviewing on Risky Injecting Practices Among Injecting Drug Users (IDUs) November 2008 August 2011
NCT00812331 Completed Phase 2 A Study to Assess the Anti-viral Activity, Safety, Tolerability and Pharmacokinetics of TMC435350 in Participants Infected With Hepatitis C-Virus (HCV) March 2009 November 2009
NCT00821587 Completed Phase 4 Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation June 2004 May 2008
NCT00825877 Completed Long-term Follow-up of HALT-C Sustained Virological Responders January 15, 2009 June 29, 2012
NCT00828789 Completed Phase 1 VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer February 2009 April 2009
NCT00833378 Completed Phase 1 Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects. January 19, 2009 March 11, 2009
NCT00845676 Completed Phase 4 Treatment of Acute Hepatitis C Virus in HIV Co-Infection March 2008 December 2013
NCT00857311 Completed Phase 1 MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED) May 2004 May 2010
NCT00866853 Completed Phase 1 TMC435-TiDP16-C107: This Study Measures the (Possible) Influence of TMC435 on the Activity of a Selected Set of Drug-degrading Proteins by Measuring the Blood Levels of Drugs That Have Been Taken Together With TMC435 and That Are Known to be Specifically Degraded by These Drug-degrading Proteins. March 2009 July 2009
NCT00879047 Completed Phase 1 Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection April 2009 April 2013
NCT00880763 Completed Phase 2 A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016) April 20, 2009 February 23, 2012
NCT00882908 Completed Phase 2 A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment June 2009 April 2011
NCT00892697 Completed Phase 2 Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV) May 2009 December 2012
NCT00903773 Completed Phase 1 VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir. June 2009 February 2010
NCT00904059 Completed Phase 1 Drug-Drug Interaction Study in Healthy Subjects May 2009 July 2009
NCT00911963 Completed Phase 1/Phase 2 Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection April 2009 September 2012
NCT00915564 Completed Phase 1 A Study to Investigate the Potential Pharmacokinetic Interaction Between TMC435 and Methadone September 2009 January 2010
NCT00001035 Completed Phase 1 The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections September 1996
NCT00917358 Completed Phase 4 Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C July 2005 June 2008
NCT00918476 Completed Phase 1 Investigation Of The Effect Of Steady State Filibuvir On The Pharmacokinetics Of Oral Contraceptives (Levonorgestrel And Ethinyl Estradiol) June 2010 February 2011
NCT00919633 Completed Phase 2 Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C June 2009 July 2012
NCT00925990 Completed Phase 2 CTS-1027 in Interferon-Naive Hepatitis C Patients June 2009 July 2010
NCT00926120 Completed Phase 2 The Effects of Mogroside Sweetener on Viral Load in TreatmenT Naive Genotype 1 (GT 1) Subjects CHC December 2008 January 2010
NCT00926146 Completed N/A Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV July 2009 February 2015
NCT00926614 Completed Phase 4 Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba September 2008 December 2011
NCT00933894 Completed Phase 1 VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram September 2009 November 2009
NCT00938860 Completed Phase 4 Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C September 2009 May 2013
NCT00938899 Completed Phase 1 TMC435350-TiDP16-C101 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing January 2007 September 2007
NCT00945880 Completed Phase 1 Safety and Tolerability Study of Clemizole Hydrochloride to Treat Hepatitis C in Subjects Who Are Treatment-Naive July 2009 August 2010
NCT00946010 Completed Investigation of Hepatitis B and Hepatitis C in Taiwan April 2008 January 2011
NCT00947349 Completed Phase 2 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients July 2009 August 2011
NCT00947440 Completed Phase 1 Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule Formulation July 2009
NCT00958152 Completed Phase 1 Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects August 2009 January 2010
NCT00958763 Completed Phase 2 Alcohol Use Reduction in Methadone Individuals With Hepatitis C Virus(HCV) March 2006 December 2008
NCT00959699 Completed Phase 2 A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4) November 2009 October 2012
NCT00973388 Completed Phase 1 VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers October 2009 January 2010
NCT00979927 Completed Phase 1 SPC3649 Multiple Dose Study in Healthy Volunteers September 2009 September 2010
NCT00979979 Completed Clinical Performance of Abbott RealTime Hepatitis C Virus (HCV) Genotype II Test July 2009 October 2013
NCT00980330 Completed Phase 2 A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment October 2009 August 2011
NCT00982826 Completed Phase 1 Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072 September 2009 January 2010
NCT00983164 Completed N/A Blood Antioxidant Status in Chronic Hepatitis C Patients Before and After Antioxidant Supplementation: a Randomized Clinical Trial January 2007 April 2009
NCT00983853 Completed Phase 2 Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV October 2009
NCT00984620 Completed Phase 2 Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3) September 2009
NCT00987337 Completed Phase 2 Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects November 2009 January 2012
NCT00993122 Completed Phase 4 Ribavirin Pre-treatment Followed by Combined Standard Therapy in Hepatitis C Virus (HCV) Recipients October 2009 February 2012
NCT00996216 Completed Phase 3 Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390 September 2009 February 2013
NCT00996879 Completed Phase 1 Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects May 2013 September 2013
NCT00998985 Completed Phase 1 A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004) February 23, 2010 November 8, 2012
NCT01008280 Completed Phase 4 Baclofen to Reduce Alcohol Use in Veterans With HCV October 2010 September 2015
NCT01010906 Completed Phase 1 A Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of Vaniprevir (MK-7009-005) July 1, 2009 June 21, 2010
NCT01025596 Completed Phase 1/Phase 2 Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1) May 2007 March 2012
NCT01033045 Completed Epidemiological Study to Evaluate the Management of Patients With Chronic Hepatitis C and Previous Treatment Failure September 2009 July 2013
NCT01038167 Completed Phase 1 A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults January 2010 April 2010
NCT01045278 Completed Phase 4 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy April 2008 September 2013
NCT01050881 Completed Notification of Donors With Positive Microbiology Markers March 2010 November 2010
NCT01051921 Completed Phase 2 Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders January 2010 December 2011
NCT01052701 Completed Phase 1 Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment December 2009 December 2012
NCT01054729 Completed Phase 2 Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients January 2010 August 2011
NCT01054742 Completed Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2) December 2009 June 2011
NCT01058512 Completed Phase 2 A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy March 2010 December 2010
NCT01070407 Completed Phase 1 A Study of a New Candidate Vaccine Against Hepatitis C Virus (HCV) July 2007 February 2011
NCT01074008 Completed Phase 2 A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 March 2010 January 2012
NCT01081483 Completed Phase 1 A Study of Single Doses of ABT-072 in Japanese Healthy Male Adults March 2010
NCT01091077 Completed Phase 1 A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection June 2009 August 2013
NCT01094873 Completed Phase 1 Study of a Novel Therapeutic Vaccine for Hepatitis C Virus November 2009 April 2013
NCT01124591 Completed Phase 2 Brief Intervention for Drug Misuse in the Emergency Department June 2010 December 2014
NCT01134952 Completed Phase 4 Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV) June 2010 December 2014
NCT01137383 Completed Phase 3 Pegaferon and Ribavirin for Hepatitis C December 2007 February 2010
NCT01143896 Completed N/A Hepatitis C Translating Initiatives for Depression Into Effective Solutions February 2012 November 2015
NCT01165359 Completed Phase 1 Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults September 2010 March 2012
NCT01180790 Completed Phase 2 Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants September 2010 April 2013
NCT01181804 Completed Phase 1 Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED) June 2010 December 2010
NCT01183169 Completed Phase 2 Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment August 2010 May 2013
NCT01192698 Completed N/A Intravenous Interferon During Liver Transplant October 2009 February 2013
NCT01197157 Completed Phase 2/Phase 3 Study of the Impact of Nitazoxanide on Chronic Hepatitis Patients September 2010 April 2014
NCT01200420 Completed Phase 2 Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects September 2010 December 2011
NCT01202825 Completed Phase 1 TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients April 2010 November 2011
NCT01208311 Completed Acoustic Liver Biopsy in Normals and in Patients With Cirrhosis Using Endoscopic Ultrasound December 2004 December 2016
NCT01215643 Completed Phase 2 Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants October 2010 May 2012
NCT01217359 Completed Phase 1 Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling May 2010 August 2012
NCT01221298 Completed Phase 2 A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) October 2010 April 2012
NCT01224197 Completed Phase 1 TMC435 HPC1004 - Phase I Study Investigating the Pharmacokinetics of TMC435 in Healthy Chinese Volunteers October 2010 January 2011
NCT01226771 Completed Phase 3 Ribavirin Loading Dose or Priming and Concentration Targeting for HCV Genotype 1 September 2010 September 2014
NCT01231685 Completed Phase 2 Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection December 2011 September 2016
NCT01253551 Completed Phase 1 VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir December 2010 April 2011
NCT01258686 Completed Phase 3 Clinical Study With Silymarin in the Patients With Chronic Hepatitis C Infection Who Failed Conventional Antiviral Therapy November 2010 August 2013
NCT01269294 Completed Phase 1 TMC435-TiDP16-C117: The Effect of TMC435 on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers January 2011 July 2011
NCT01272479 Completed Prohepcidin, Inflammation and Iron Homeostasis in Hemodialysis Patients With Chronic Hepatitis C August 2008 March 2010
NCT01273948 Completed Phase 1/Phase 2 Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection January 2011 February 2012
NCT01275599 Completed Phase 1 Drug-Drug Interaction Study Between Telaprevir and Buprenorphine January 2011
NCT01277692 Completed Phase 1 A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients. November 3, 2010 May 9, 2011
NCT01281839 Completed Phase 3 An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy February 2011 February 2013
NCT01285050 Completed Phase 4 Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds January 2011 April 2015
NCT01289782 Completed Phase 3 An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients February 2011 January 2013
NCT01289951 Completed Phase 1 Pharmacokinetic Study of Raltegravir in Human Immunodeficiency Virus/Hepatitis C Virus (HIV/VHC) Coinfected Patients With Advanced (Child-Pugh C) Hepatic Cirrhosis December 2010 October 2011
NCT01290679 Completed Phase 3 An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants March 2011 February 2013
NCT01292161 Completed Phase 2 Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis C March 2006 September 2006
NCT01292824 Completed Phase 1 Pilot Study of Hepatitis C Virus Entry Inhibitor (ITX 5061) in Liver Transplant Recipients February 2011 May 2013
NCT01293279 Completed HCV (Hepatitis C Virus) Viral and Host Genotyping (IL28B, Interleukin 28B) in China February 2011 June 2011
NCT01297270 Completed Phase 3 Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2) April 2011 April 2014
NCT01306617 Completed Phase 2 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection February 2011 October 2012
NCT01308606 Completed Phase 1 TMC435-TiDP16-C116 - Relative Bioavailability and Food Effect Study March 2011 June 2011
NCT01309932 Completed Phase 2 Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin March 2011 September 2014
NCT01317784 Completed N/A Behavioral Science Aspects of Rapid Test Acceptance May 2011 August 2014
NCT01318694 Completed Phase 3 Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants March 2011 August 2013
NCT01323244 Completed Phase 3 A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study December 2011 March 2015
NCT01329913 Completed Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003) May 2011 April 2012
NCT01330316 Completed Phase 3 A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients July 2011 June 2014
NCT01335607 Completed Phase 1 A Open-label Study to Evaluate the Relative Bioavailability of Samatasvir (IDX184) and Food Effect in Healthy Male Participants (MK-2355-006) April 2011 May 2011
NCT01336829 Completed Phase 1 TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir. March 2011 September 2011
NCT01343888 Completed Phase 3 Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1) April 2011 March 2014
NCT01349465 Completed Phase 3 3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection July 4, 2011 January 5, 2016
NCT01350648 Completed Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection August 23, 2011
NCT01355107 Completed Comparison of Selenium Levels in HCV- Infected Patients at Different Stages of Disease April 2011 December 2011
NCT01389323 Completed Phase 3 BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C September 2011 January 2014
NCT01390428 Completed Phase 1 Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013) July 28, 2011 September 12, 2014
NCT01405183 Completed Association Between Hepatitis C Infection and Renal Cell Carcinoma January 2011 September 2013
NCT01410123 Completed N/A Integrated Stepped Care for Unhealthy Alcohol Use in HIV January 2013 August 31, 2018
NCT01413490 Completed Hepatitis C Rimantadine and Antiviral Combination Therapy May 2012 March 2015
NCT01419899 Completed Phase 2/Phase 3 Increasing Viral Testing in the Emergency Department January 2011 January 2012
NCT01423643 Completed HCV/HIV Coinfection: Antiviral Therapy and Fibrosis March 2001 October 2015
NCT01424540 Completed Phase 1 Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805 September 1, 2011 October 3, 2011
NCT01427504 Completed N/A Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers August 2011 March 2012
NCT01429155 Completed Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B August 2011 March 2013
NCT01431898 Completed Phase 1 Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection September 2011 May 2012
NCT01436357 Completed Phase 1/Phase 2 Staged Phase I/II Hepatitis C Prophylactic Vaccine March 6, 2012 May 25, 2018
NCT01441180 Completed Phase 1/Phase 2 GS-7977 With Ribavirin for Hepatitis C (SPARE) September 2011 July 2014
NCT01442311 Completed N/A Directly Observed Hepatitis C Treatment in Methadone Clinics October 2007 March 2013
NCT01445795 Completed Phase 1/Phase 2 Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects September 2011 May 2012
NCT01447680 Completed Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing August 2011 December 2012
NCT01448044 Completed Phase 3 Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C December 2011 January 2014
NCT01448915 Completed Management of Hepatitis C in HIV Infected Injection Drug Users (IDUs) March 31, 2021 March 31, 2021
NCT01458054 Completed Phase 1 Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults September 27, 2011 November 28, 2011
NCT01458080 Completed WEUSKOP5410: Observational Study in ENABLE Clinical Trials May 2011 November 2013
NCT01466790 Completed Phase 2 A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients January 2012 January 2014
NCT01469884 Completed Phase 4 Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients November 2011 April 2015
NCT01472354 Completed N/A Feasibility of a Hepatitis C Virus (HCV) Decision-Making Intervention Among HIV-infected Adults October 2010 November 2012
NCT01474811 Completed HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network November 2011 September 9, 2022
NCT01482390 Completed Phase 2 A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C November 30, 2011 January 31, 2014
NCT01482767 Completed Phase 3 Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection April 2012 April 2015
NCT01485991 Completed Phase 3 TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy February 2012 April 2014
NCT01492426 Completed Phase 3 Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection January 2012 March 2014
NCT01492504 Completed Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial February 7, 2012 March 19, 2018
NCT01497327 Completed Phase 1 Open-Label Hepatic Impairment Study July 2011 January 2012
NCT01497366 Completed Phase 3 Phase 3 Study of Sofosbuvir and Ribavirin December 2011 April 2013
NCT01497834 Completed Phase 3 A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients January 2012 June 2013
NCT01499498 Completed Phase 1 The Boceprevir and Sildenafil Pharmacokinetics Study December 2012 May 2014
NCT01517529 Completed Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations January 2012 December 2014
NCT01525810 Completed Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial March 2012 November 2014
NCT01534728 Completed Identification of Hepatitis C Virus (HCV) Specific T Cells February 2012 March 2014
NCT01537900 Completed Phase 1 A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010) October 1, 2013 July 31, 2014
NCT01559844 Completed Phase 2 Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant March 2012 October 2014
NCT01565889 Completed Phase 1/Phase 2 Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients. March 2012 November 2013
NCT01567735 Completed Phase 3 A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients March 27, 2012 March 20, 2014
NCT01579474 Completed Phase 3 Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial April 2012 December 2013
NCT01580306 Completed Phase 1 Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment April 2012 June 2012
NCT01582035 Completed Phase 1 Study to Examine Multiple Doses of TMC647055 in Combination With Telaprevir April 2012 November 2013
NCT01585584 Completed Phase 3 Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment May 2012 July 2015
NCT01591668 Completed Phase 1 A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C March 2012 December 2012
NCT01593735 Completed Phase 1 A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1) May 2012 February 2013
NCT01619475 Completed Adult-to-Adult Living Donor Transplant Cohort Study February 2011 August 2014
NCT01637922 Completed Phase 1 Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone August 2012 November 2012
NCT01646489 Completed Phase 1 Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects June 2012 September 2012
NCT01647191 Completed N/A Reducing Hepatitis C Virus (HCV)/Human Immunodeficient Virus (HIV) Risk Behaviors Among Injection Drug Users in China July 1, 2011 May 31, 2015
NCT01663922 Completed Phase 1 Boceprevir and Ucalm (St John&Apos;s Wort) August 2012 December 2012
NCT01667081 Completed Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017) October 17, 2012 March 31, 2021
NCT01667731 Completed Phase 3 Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults July 2012 February 2014
NCT01681420 Completed N/A Improving Blood Safety and HIV Testing in Brazil August 1, 2012 January 31, 2015
NCT01682720 Completed Phase 3 Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection September 2012 January 2014
NCT01687257 Completed Phase 2 Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation July 2012 October 2015
NCT01701336 Completed Phase 1 Study of a Novel Therapeutic Vaccine Against Hepatitis C Using Ad6NSmut and MVA-NSmut in Chronically Infected Patients March 2012 February 2013
NCT01704846 Completed Phase 1 Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules October 2012 January 2013
NCT01707030 Completed N/A Web-based Intervention to Reduce Alcohol Use in Veterans With Hepatitis C March 1, 2015 June 29, 2018
NCT01707472 Completed Phase 2 Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis October 4, 2012 October 17, 2014
NCT01715779 Completed Follow-up Study of Patients Who Experienced Thromboembolic Events in the ENABLE Studies August 2012 June 2015
NCT01716156 Completed Phase 2 A Study of Different Durations of Treatment With Grazoprevir (MK-5172) in Combination With Ribavirin in Participants With Chronic Hepatitis C (MK-5172-039) January 18, 2013 March 12, 2014
NCT01717326 Completed Phase 2 A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035) February 7, 2013 May 6, 2015
NCT01718158 Completed Phase 3 Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy January 2013 October 2014
NCT01718301 Completed Phase 3 HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin March 2013 June 2015
NCT01726400 Completed In Hepatitis C Patients Treated With Interferon and Ribavirin, Does Hepcidin Contribute to Treatment Induced Anaemia December 2012 July 2014
NCT01732848 Completed A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189) November 2012 June 2014
NCT01740089 Completed Phase 2/Phase 3 Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C November 2011 December 2013
NCT01756079 Completed Phase 4 A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105) February 6, 2013 November 17, 2015
NCT01772121 Completed Observational Study on Prevalence of Host and Viral Genotypes in Chronic Hepatitis B and Hepatitis C Patients in India May 2012 October 2012
NCT01773070 Completed Phase 3 A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study June 2013 October 2016
NCT01790633 Completed N/A Pilot Study Evaluating the Use of Simultaneous HBV, HCV, and HIV Rapid Tests February 2013 October 2013
NCT01795911 Completed Phase 2 Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin March 2013 September 2014
NCT01808248 Completed Phase 2 Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3 February 2013 December 2013
NCT01816490 Completed Phase 2 THISTLE - The HIV-HCV Silibinin Trial April 2013 December 2014
NCT01825980 Completed Phase 1/Phase 2 Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients March 2013 December 2014
NCT01827657 Completed Phase 1 Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects May 28, 2013 March 20, 2014
NCT01830205 Completed Phase 1 Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment September 2012 June 2013
NCT01838772 Completed Phase 4 HCV Treatment in HIV Co-Infected Patients in Asia December 2013 September 2016
NCT01840722 Completed N/A Brief Intervention for Rural Women at High Risk for HIV/HCV December 2012 May 2019
NCT01842451 Completed Phase 2 A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C June 2013 May 2014
NCT01844414 Completed N/A UCLA-Amity Parolee Health Promotion Study February 2010 May 2015
NCT01846494 Completed Longitudinal Assessment of Cardiovascular and Renal Health in Patients With Hepatitis-C (CARE-Hep C) May 10, 2013 March 19, 2018
NCT01856426 Completed Phase 1 Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects June 2013 October 2015
NCT01857245 Completed N/A Intensive Models of HCV Care for Injection Drug Users October 1, 2013 March 1, 2017
NCT01858766 Completed Phase 2 Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection April 2013 August 2014
NCT01878799 Completed Phase 2 Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV June 2013 September 2014
NCT01886599 Completed Phase 1 Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney Disease November 2012 February 2013
NCT01888900 Completed Phase 2 New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C May 2013 November 2015
NCT01889433 Completed Phase 3 An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C July 10, 2013 December 2, 2015
NCT01896193 Completed Phase 3 Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection June 2013 June 2014
NCT01899092 Completed Phase 1/Phase 2 Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C January 2014 November 2016
NCT01909778 Completed Phase 1 Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis June 2008 October 2008
NCT01909804 Completed Phase 2 Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection June 2013 August 2014
NCT01910636 Completed Phase 3 Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection February 2013 June 2014
NCT01912495 Completed Phase 2 Dutch Acute HCV in HIV Study (DAHHS) August 2013 January 2016
NCT01921400 Completed The Pathogenesis of Hepatitis C Virus Vertical Transmission January 2013 December 2017
NCT01924949 Completed Phase 2 Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection July 2013 August 2014
NCT01930058 Completed Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003) October 2, 2013 May 5, 2014
NCT01932762 Completed Phase 2 Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047) October 1, 2013 December 4, 2014
NCT01937728 Completed Phase 4 Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1) March 2010 December 2016
NCT01957085 Completed Undiagnosed Hepatitis C Infection in an Urban Hospital June 2014 January 2016
NCT05248919 Enrolling by invitation N/A Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan June 1, 2023 December 2024
NCT05376371 Enrolling by invitation N/A Criminal Justice Coordinated Transitional Care November 29, 2022 June 2025
NCT02699736 Enrolling by invitation EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV January 1994 December 2030
NCT01508286 No longer available Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects
NCT05769400 Not yet recruiting Awareness of Osteoporosis in Patients With Hepatitis C Infection July 1, 2023 August 1, 2024
NCT06203925 Not yet recruiting Hepatitis C Virus Self-testing (HCVST) in Sexual and Gender Minorities in Rio de Janeiro January 8, 2024 December 31, 2025
NCT05467826 Not yet recruiting Phase 4 Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis September 1, 2022 December 31, 2023
NCT06373198 Not yet recruiting Implementation of a Re-engagement Program for Hepatitis C Patients Lost to Follow-up in Argentina. May 1, 2024 January 15, 2025
NCT05692505 Not yet recruiting Multicenter Performance Study of QuadQuik Invitro Diagnostic Device April 1, 2023 June 1, 2023
NCT06263829 Not yet recruiting N/A HCV Tappt Adherence Study July 1, 2024 July 1, 2025
NCT06159504 Not yet recruiting Early Phase 1 Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania March 2024 December 2026
NCT06409169 Not yet recruiting N/A DBS TaT in Peer-assisted Telemedicine for Hepatitis C May 2024 May 2026
NCT05102838 Not yet recruiting Prospective Cohort Study on Prognosis of Patients With Hepatitis B/C November 1, 2021 March 31, 2026
NCT03767231 Not yet recruiting N/A ED Patient's Perceptions and Acceptability Toward a Novel POC HCV Viral Load Testing November 2025 November 2027
NCT06316492 Not yet recruiting A Study Done by a Demonstrator and Two Professors in Public Health and Community Medicine Department in Faculty of Medicine in Assiut and New Valley University to Assess Knowledge, Attitude ,and Practice of Rural Population in a Remote Governorate ( New Valley ) Towards Hepatitis B and C Viruses August 1, 2024 June 1, 2026
NCT05813691 Not yet recruiting Epidemiology of Occult Hepatitis C Virus Infection in Patients Born Before 1969 in the Hospital Setting: a Spontaneous Opportunistic Screening Initiative. April 10, 2023 April 10, 2025
NCT02275221 Recruiting Immune Response in Patients With Hepatitis B and C Infection August 2013 December 2024
NCT05466331 Recruiting N/A Rural New England Health Study (Phase 2) May 18, 2022 July 31, 2024
NCT02995252 Recruiting The HOPE Study: Characterizing Patients With Hepatitis B and C December 2014 December 2025
NCT03855917 Recruiting Phase 4 Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir February 11, 2020 February 2026
NCT03025074 Recruiting Blood Collection Biorepository for Liver Disease Research July 2013 December 2099
NCT05248555 Recruiting The National Australian HCV Point-of-Care Testing Program - Minimal Dataset December 1, 2021 December 2026
NCT05582681 Recruiting Phase 4 HCV Test and Treat Utilizing Simplified HCV Patient Education November 11, 2022 October 2027
NCT05208697 Recruiting N/A Tele-Harm Reduction October 7, 2022 April 30, 2025
NCT02647879 Recruiting Treatment as Prevention for Hepatitis C in Iceland January 2016 May 2031
NCT04585165 Recruiting User-friendly HIV Testing and Counseling Services October 19, 2020 December 2024
NCT01280825 Recruiting The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing January 14, 2011 December 14, 2027
NCT05624086 Recruiting N/A Hepatic Enzymes, Psychological Measures, and Sexual Dysfunction Responses to Aerobic Exercise in Hepatitis-C Men October 15, 2022 April 15, 2023
NCT03086044 Recruiting Phase 4 Transplanting Hepatitis C Positive Organs March 1, 2017 December 2023
NCT06010524 Recruiting A Study of Chronic Hepatitis C Patients Treated With SOF/VEL/VOX February 1, 2023 December 31, 2023
NCT05016609 Recruiting Phase 4 Same-visit Hepatitis C Testing and Treatment (The QuickStart Study) March 9, 2022 June 2024
NCT05042544 Recruiting The National Australian HCV Point-of-Care Testing Program February 22, 2022 December 2026
NCT05067374 Recruiting Hepatitis C Screening Paired With Mammography March 23, 2022 March 23, 2025
NCT03944447 Recruiting Phase 2 Outcomes Mandate National Integration With Cannabis as Medicine December 1, 2018 December 31, 2025
NCT00001971 Recruiting Evaluation of Patients With Liver Disease May 27, 1992
NCT03135886 Recruiting N/A Project I Test: Implementing HIV Testing in Opioid Treatment Programs June 12, 2017 January 31, 2025
NCT05181826 Recruiting Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer May 21, 2019 December 2025
NCT05146609 Recruiting N/A Acceptance of Hepatitis C Screening by Self-testing in High Risk and General Population February 1, 2022 June 2024
NCT04493385 Recruiting The Hepatitis C Transplant Collaborative September 16, 2019 December 2023
NCT03981211 Recruiting N/A Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs February 12, 2021 February 12, 2025
NCT04017338 Recruiting Phase 3 Transplantation Using Hepatitis C Positive Donors, A Safety Trial August 6, 2018 December 31, 2024
NCT04620226 Recruiting Phase 4 UHN Inpatient Hepatitis C & B Screening February 1, 2024 July 2025
NCT04014179 Recruiting N/A Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs July 27, 2022 December 31, 2025
NCT04508907 Recruiting Phase 4 A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients September 10, 2020 December 31, 2024
NCT04162938 Recruiting N/A Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum March 24, 2022 April 2026
NCT04411381 Recruiting N/A Telemedicine-based Model of Care for the Management of Hepatitis C Infected Patients May 25, 2020 December 2023
NCT04405024 Recruiting N/A Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients September 21, 2020 August 21, 2024
NCT04701437 Recruiting N/A Advanced Care Coordination and Enhanced Linkage and Retention Among Transitional Re-Entrants December 17, 2021 March 31, 2024
NCT03685045 Recruiting N/A ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings May 28, 2018 January 30, 2025
NCT05413785 Recruiting N/A Hepatitis C Treatment in Probation and Parole Office August 23, 2022 December 31, 2024
NCT05361603 Recruiting Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Structures May 24, 2017 February 14, 2030
NCT01644903 Recruiting Proteogenomic Monitoring and Assessment of Liver Transplant Recipients April 2010 December 2025
NCT05713136 Recruiting The National Australian HCV Point-of-Care Testing Program - HCV Antibody Testing Minimal Dataset January 25, 2023 January 2027
NCT06380166 Recruiting N/A Hepatitis C Lab Testing Comparison Study June 13, 2024 September 2024
NCT05839522 Recruiting Australian Hepatitis and Risk Survey in Prisons April 27, 2022 May 1, 2023
NCT05868005 Recruiting N/A Delivering a Multi-disease Screening Tool to Migrant Populations October 23, 2023 September 2024
NCT06367465 Recruiting Feasibility and Acceptability of HCV Treatment in Pregnancy February 1, 2024 February 28, 2026
NCT06349902 Recruiting Re-link HCV in Substance-Use Telemedicine Program March 12, 2024 December 31, 2024
NCT05904470 Recruiting Phase 2 A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV May 30, 2023 September 2024
NCT06179498 Recruiting N/A Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs March 25, 2024 December 31, 2027
NCT06369116 Recruiting N/A Trial of Hepatitis C Self-Testing in the Hands of Untrained Lay Users October 12, 2023 April 22, 2024
NCT06306300 Recruiting Phase 4 Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil) July 4, 2022 December 31, 2025
NCT00493610 Suspended N/A Mucomyst for Hepatitis C November 2006 June 2008
NCT02935478 Suspended N/A Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation October 18, 2017 December 2024
NCT02895958 Terminated Phase 4 The Dublin Zepatier Study March 15, 2018 December 6, 2019
NCT00158535 Terminated Phase 2 Liver Transplantation in Patients With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Coinfection June 2002
NCT00229749 Terminated Phase 1/Phase 2 Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients September 2005 January 2007
NCT02590068 Terminated N/A Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination December 2015 September 8, 2017
NCT01500772 Terminated Phase 3 Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C March 2012 May 2012
NCT01467505 Terminated Phase 2 An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients February 2012 April 2014
NCT01273064 Terminated Phase 2 Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders January 2011 October 2011
NCT00456248 Terminated Phase 4 Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin February 2007 October 2007
NCT01467492 Terminated Phase 4 Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C January 2012 May 2014
NCT00725842 Terminated Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed) January 2009 June 2011
NCT01250743 Terminated N/A A Pilot Study of High-Dose, Intravenous Ascorbic Acid (Vitamin C) to Treat Hepatitis C January 2009 June 2012
NCT03625687 Terminated Phase 4 Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant February 5, 2019 April 4, 2022
NCT00742326 Terminated Phase 4 Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections August 2008 January 2013
NCT01425970 Terminated Phase 2 Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin May 2012 August 2013
NCT02605304 Terminated Phase 2 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF February 17, 2016 March 20, 2017
NCT01567540 Terminated Phase 1 A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients March 2013 January 2014
NCT01833845 Terminated Phase 1/Phase 2 Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C April 2013 April 2014
NCT01446250 Terminated Phase 3 Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1 December 2011 May 2013
NCT00260208 Terminated Phase 4 Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus January 2006
NCT00114712 Terminated The Ribavirin Pregnancy Registry January 2004 November 2, 2020
NCT01582594 Terminated A Registration Study to Evaluate the Performance of CHIRON® RIBA® HCV 3.0 SIA in HCV Antibody Detection February 2012 January 2013
NCT02956629 Terminated Phase 2 Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041) November 16, 2016 March 5, 2018
NCT00768001 Terminated Genetic Analysis of Liver Cancer June 2008 October 2011
NCT03253471 Terminated Phase 1 A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus Infection July 7, 2017 September 18, 2017
NCT01592006 Terminated Phase 4 Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients April 2012 September 2014
NCT02438917 Terminated Biomarkers of Liver Fibrosis June 2015 March 3, 2017
NCT01470651 Terminated Phase 4 Armodafinil for Patients Starting Hepatitis C Virus Treatment October 2011 June 2014
NCT02315638 Terminated Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034. November 2014 September 24, 2018
NCT02628691 Terminated Monitoring Liver Disease Progression in Hepatitis C/HIV Co-infected Patients With No-to-moderate Fibrosis, in Phnom Penh, Cambodia December 17, 2015 July 12, 2017
NCT00810875 Terminated Study of Maternal Hepatitis C Infection and Influenza Vaccination in Pregnancy April 2009 August 2010
NCT03221582 Terminated Phase 4 Impact of Hepatitis C Therapy and Bone Health August 28, 2017 November 30, 2018
NCT01332552 Terminated Phase 1 A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects January 14, 2011 April 6, 2011
NCT01890083 Terminated Phase 2/Phase 3 A Health Intervention to Prevent Depression Hepatitis C Patients June 2013 October 2015
NCT00705107 Terminated Adherence to Treatment With PegIntron Pen Plus Rebetol in Treatment-naïve Adult Patients With Hepatitis C in Romania (Study P04247) November 2004 November 2007
NCT03804814 Terminated N/A Motivational Interviewing for HCV Elimination May 21, 2019 October 4, 2021
NCT00767936 Terminated Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocellular Carcinoma March 2008 September 2013
NCT01182298 Terminated Open Label Study to Evaluate Chronic Hepatitis C Treatment in Latino Subjects With and Without HIV Co-infection July 2010 March 2013
NCT01467479 Terminated Phase 3 A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV) December 2011 February 2014
NCT01721265 Terminated 3-Year Observational Virology Follow-up Study in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals October 2012 March 2015
NCT00277758 Terminated Phase 1 Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I March 2004 August 2006
NCT00239733 Terminated Phase 4 Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection March 2005 February 2010
NCT02568540 Terminated C Tracker, Hepatitis C, Care & Collaboration - Patient Reported Outcomes Survey Study October 2015 January 16, 2019
NCT00871845 Terminated N/A Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients September 2008 August 2011
NCT01433133 Terminated Phase 1/Phase 2 Safety and Biological Activity of InfraDure Biopump Secreting Sustained Interferon in HCV Patients October 2012 March 2014
NCT04057001 Terminated Hepatitis C Positive Organ to Recipient Hepatitis C Negative Longitudinal Transplant Study July 1, 2019 March 6, 2023
NCT03441542 Terminated N/A Registry-based HCV Care Cascade Navigation at Atlanta's Grady Memorial Hospital July 23, 2018 February 15, 2019
NCT01387958 Terminated Phase 2 A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients July 2011 February 2012
NCT02940691 Terminated Phase 4 Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs May 1, 2017 November 1, 2018
NCT03208244 Terminated Phase 4 DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant November 9, 2017 April 28, 2021
NCT03208127 Terminated Phase 4 DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant November 21, 2017 June 4, 2021
NCT03099135 Terminated Phase 3 A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection April 10, 2017 February 13, 2018
NCT00164060 Terminated Associations, Outcomes and Genomics of GB Virus C, Hepatitis C Virus and Human Immunodeficiency Virus Infection February 2004 May 2007
NCT03487848 Terminated Phase 2 Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection June 25, 2018 September 17, 2020
NCT05184283 Terminated Utilization of MAsS in Patients Undergoing LT for HCC June 16, 2022 November 29, 2023
NCT02613403 Terminated Phase 2 Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021) December 10, 2015 March 27, 2017
NCT03125408 Terminated Clinical Performance Evaluation of DxN HCV Assay May 2, 2012 August 30, 2017
NCT02455167 Terminated Phase 3 Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis May 2015 July 18, 2016
NCT03534141 Terminated N/A Mild Hypothermia and Acute Kidney Injury in Liver Transplantation July 7, 2018 September 14, 2023
NCT01821625 Terminated Phase 2/Phase 3 Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C April 2013 April 2016
NCT00655226 Terminated N/A Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients March 2008 May 2010
NCT00350714 Terminated Phase 2 BreathID Multi-center HCV Liver Breath Test Study July 2006 February 2007
NCT01701063 Terminated Phase 1/Phase 2 An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus January 2013 April 2015
NCT02120274 Terminated Phase 4 Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C March 2014 May 2016
NCT00727077 Terminated Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED) June 2006 June 2007
NCT02503735 Terminated N/A Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD) July 15, 2015 May 2019
NCT02194998 Terminated Phase 2 Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy September 16, 2015 November 13, 2018
NCT00977054 Terminated Phase 4 Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load September 2009 December 2012
NCT04499651 Terminated N/A Testing of a Navigation Intervention for Hepatitis C and HIV July 31, 2020 February 22, 2021
NCT00439959 Terminated Phase 1 Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults October 2006 March 2007
NCT01329952 Unknown status Reinfection and Long Term Outcomes in Intravenous Drug Users (IVDUs) After Hepatitis C Treatment May 2011 June 2014
NCT03444272 Unknown status Phase 3 Effect of Direct-acting Antiviral Drugs on Erectile Function January 1, 2018 December 2022
NCT03456440 Unknown status The Use of MRI Apparent Diffusion Coefficient Value (ADC Value) to Assess Liver Cirrhosis April 2019 May 2020
NCT01350167 Unknown status N/A Screening for Liver Cancer With CT vs. Ultrasound in Patients With Advanced Liver Disease November 2001 December 2021
NCT01426204 Unknown status Efficacy, Safety and Adherence of Patients Infected With Hepatitis C Virus in Retreat With INFERGEN (Interferon Alfacon1) September 2011 August 2013
NCT04510246 Unknown status N/A Link Hepatitis C Notifications to Treatment in Tasmania September 8, 2020 March 30, 2022
NCT03524794 Unknown status HepCare: The Effectiveness of Community Based Interventions With Peer Support to Improve Case Detection, Carry Out Pre-treatment Assessments and Assist Underserved Populations Through HCV Treatment August 8, 2017 March 31, 2019
NCT00281502 Unknown status Phase 2 The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy December 2005 December 2012
NCT00300807 Unknown status Phase 1 Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection October 2005 April 2007
NCT04525833 Unknown status Liver Disease and Other Systemic Diseases January 1, 2020 December 31, 2021
NCT03551002 Unknown status Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego January 1, 2018 December 31, 2021
NCT04550273 Unknown status N/A Leptin and Liver Enzymes Responses to Aerobic Training in Hepatitis c Patients February 9, 2020 March 2021
NCT02646111 Unknown status Phase 3 Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Protease-Inhibitors ("PI") Failures January 2016 January 2019
NCT01473849 Unknown status Impact of Cytomegalovirus (CMV) Replication Over Hepatitis C Recurrence in Liver Transplant Recipients May 2010 April 2013
NCT02657694 Unknown status Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods July 1, 2015 June 30, 2018
NCT01492478 Unknown status Psychobiological Characterization of Depression in Hepatitis C January 2012 December 2015
NCT03591783 Unknown status Impact of Sustained Virologic Response on Glycemic Control Among Diabetic Patients With Hepatitis C Virus Related Liver Disease August 2018 December 2019
NCT04618679 Unknown status Application of 18F-FDOPA PET in Research of the Association Between HCV Infection and Parkinson's Disease. November 2, 2020 June 30, 2021
NCT00437476 Unknown status Phase 3 Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy February 2007 December 2010
NCT00437684 Unknown status Phase 3 Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy February 2007 December 2010
NCT02687061 Unknown status Chronic Hepatitis B and C Recall Northern Holland February 2016 December 2016
NCT04625322 Unknown status Phase 4 HCV Treatment Initiation During Acute Psychiatric Admission April 19, 2022 April 2023
NCT00495768 Unknown status N/A Reducing Depressive Symptoms During HCV Therapy: A Randomized Study July 2004 December 2007
NCT02732405 Unknown status Phase 3 Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis May 2016 March 2017
NCT04662138 Unknown status Safety and Efficacy of Different Antiviral Regimens for Hepatitis C Virus Relapse August 24, 2020 May 28, 2022
NCT02745132 Unknown status Phase 4 Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC) June 2016 December 2017
NCT01594554 Unknown status A 5-year Observational Follow-up Study to Describe Treatment Patterns in Real World of HCV Patients in China. April 2012 September 2016
NCT01603108 Unknown status Phase 2 Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant March 2012 December 2018
NCT02768545 Unknown status Phase 4 Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) June 2013 June 2016
NCT00069511 Unknown status Phase 2 12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy. July 2003 December 2004
NCT04717856 Unknown status N/A Evaluation of the Use of the GenXpert to Detect Hepatitis C RNA October 21, 2020 October 21, 2021
NCT02772744 Unknown status Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4 November 1, 2017 December 31, 2018
NCT00638144 Unknown status Prevention of Graft Reinfection After Liver Transplantation With Anti HCV Monoclonal Antibodies Identified in Chronically Infected Patients or in Patients With Resolved Hepatitis C February 2008 December 2015
NCT02802280 Unknown status Phase 4 Endothelial Dysfunction and Subclinical Atheromatosis in Chronic HCV Infection. Response to DAA Agents. October 2015 March 2017
NCT00701272 Unknown status FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver Transplantation June 2008 December 2014
NCT03775798 Unknown status Incidence of de Novo Hepatocellular Carcinoma After Antiviral Agents for HCV. May 1, 2016 January 1, 2021
NCT02856243 Unknown status Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia Vasculitis November 2013
NCT03776760 Unknown status Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination May 28, 2019 August 2022
NCT04885855 Unknown status Phase 2/Phase 3 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C March 23, 2021 December 31, 2022
NCT01727934 Unknown status Phase 2 Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C November 2012 April 2014
NCT02897596 Unknown status Phase 3 Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients April 28, 2017 October 30, 2019
NCT04891445 Unknown status N/A Hepatitis C in Severe Mental Disorders: Nursing Programme June 1, 2021 December 31, 2023
NCT02904603 Unknown status Immune Monitoring of Hepatitis C Under DAA Therapy November 2014 January 2017
NCT00188201 Unknown status Neurocognitive Functioning in Patients With Hepatitis C Pre- and Post-Treatment With Antiviral Medication January 2002
NCT00164073 Unknown status Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection February 2004 February 2007
NCT03813498 Unknown status N/A Hepatitis C Patient Management and Family Health Education January 2019 November 2019
NCT02959684 Unknown status Strategic Screening for Infectious Diseases (Tuberculosis, HIV, HBV, HCV) Amongst Migrants in France April 14, 2017 July 2019
NCT02961426 Unknown status Phase 2/Phase 3 Strategic Transformation of the Market of HCV Treatments September 2016 March 2024
NCT04948801 Unknown status SOF/VEL±RBV: Efficacy and Safety in GT 3 and 6 HCV Patients December 8, 2018 December 30, 2021
NCT04959643 Unknown status Systematic Screening for Viral Hepatitis B and C at the PASS Consultation of the Montpellier University Hospital October 5, 2021 October 2023
NCT04961723 Unknown status N/A HCV Self-testing in Georgia December 10, 2021 August 2022
NCT04971538 Unknown status N/A HCV Self-testing in Pakistan November 29, 2021 April 2022
NCT00822991 Unknown status N/A Sonazoid Enhanced Liver Cancer Trial for Early Detection January 2009 December 2019
NCT03876470 Unknown status Conquering Hepatitis C Via Micro-Elimination in Southwest Virginia May 15, 2019 November 30, 2020
NCT04982718 Unknown status N/A HCV Self-testing in Malaysia September 14, 2021 April 2022
NCT00841243 Unknown status Phase 4 Nutritional Support During Antiviral Therapy for Hepatitis C March 2009 August 2010
NCT03891550 Unknown status Phase 3 Micro-elimination of Hepatitis C Virus Infection in Uremics May 13, 2019 April 15, 2024
NCT00856804 Unknown status Phase 2 Thalidomide Plus Peginterferon and Ribavirin in Patients With Interferon Resistance March 2009 June 2012
NCT03061032 Unknown status Phase 3 Treatment of Hepatitis C Virus Infection With Generic Sofosbuvir/Ledipasvir in Iranian Patients March 2017 July 2019
NCT03895294 Unknown status N/A Effect of Strategies for the Treatment of Chronic Hepatitis C in Colombia April 1, 2019 November 30, 2020
NCT05103085 Unknown status Screening for Hepatitis C Using a Rapid Diagnostic Orientation Test (TROD) in Patients Over 50 Years Old in the Digestive Endoscopy Department of the Europeen Hospital Marseille January 24, 2022 September 2023
NCT00160940 Unknown status Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis February 2002
NCT03973502 Unknown status N/A Application of 18F-FDOPA PET and Magnetic Resonance Spectroscopy (MRS) With HCV and PD June 12, 2017 May 31, 2023
NCT02044042 Unknown status Vertical Transmission of Hepatitis C Virus October 2014 July 2016
NCT03166280 Unknown status Hepatitis c and Vitamin D and Iron Status June 2017 May 2018
NCT03169348 Unknown status N/A The Effect of Direct Antiviral Therapy on Hepatitis c Virus-related Thrombocytopenia November 1, 2017 September 2019
NCT03992313 Unknown status N/A Community Versus Facility-based Services to Improve the Screening of Active HCV Infection in Cambodia August 1, 2019 October 31, 2020
NCT00980161 Unknown status Micro RNA-122 and the Clinical Course of Patients With Chronic Hepatitis C September 2009 December 2010
NCT00154531 Unknown status Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by SELDI August 2004 May 2005
NCT02102451 Unknown status Control and Elimination Within Australia of Hepatitis C From People Living With HIV July 2014 December 2022
NCT03212833 Unknown status Impact of Insulin Resistance on Therapeutic Response for Oral Treatment of Chronic Hepatitis C Virus Infection May 1, 2017 December 1, 2018
NCT01024894 Unknown status Phase 1/Phase 2 Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in Asiatic HCV Patients Resistant to Bitherapy January 2009 December 2012
NCT01025297 Unknown status Phase 1/Phase 2 Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone July 2008 March 2013
NCT03226717 Unknown status Effects of Direct Antiviral Agents on Hepatitis C Virus Arthropathy August 10, 2017 December 10, 2017
NCT04048850 Unknown status Zepatier in Patients With Substance Use September 20, 2019 December 31, 2022
NCT04061551 Unknown status N/A Eliminate Hepatitis C/EC Partnership Evaluation Protocol December 2016 December 31, 2021
NCT02150291 Unknown status Phase 4 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. May 2014 November 2015
NCT03241823 Unknown status Assessment of Patients With Hepatitis C Virus Related Liver Cirrhosis After Sustained Response to Direct Acting Anti Viral Drugs. December 1, 2017 March 2019
NCT04063839 Unknown status HCV Treatment in a Low-threshold Clinic January 2015 December 2022
NCT03247296 Unknown status Study of the Early Occurrence of Hepatocellular Carcinoma (HCC) in Egyptian HCV Infected Patients Receiving Sofosbuvir and Daclatasvir February 28, 2017 November 10, 2017
NCT04122066 Unknown status the Pulmonary Safety of Antihepatitis C Treatment June 2020 December 2023
NCT01105611 Unknown status Phase 4 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users August 2010 December 2012
NCT01108614 Unknown status Phase 3 Injecting Drug Use Community Intervention Trial June 2009 March 2011
NCT02215525 Unknown status Phase 3 Treatment of Chronic HCV Infected Egyptian Patients With Electromagnetic Waves and Herbal Therapy April 2014 May 2015
NCT02261662 Unknown status N/A Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV Infection June 2014 November 2014
NCT01146626 Unknown status N/A Does Vitamin D Improves Sustained Virologic Response (SVR) in Genotype 2,3 Chronic Hepatitis C Patients? August 2011 May 2012
NCT03254901 Unknown status Detection of Hepatitis C Infection by Oraquick Test Among Health Care Workers January 1, 2018 July 1, 2018
NCT03268317 Unknown status Neuropsychiatric Adverse Effects in Patients With Chronic Hepatitis C Treated by Direct Acting Antiviral Drugs January 2018 January 2020
NCT04153708 Unknown status N/A Retrieval of Hepatitis C Patients Lost to Follow-up November 3, 2019 September 1, 2021
NCT04191018 Unknown status GastrOesophageal Varices After Sustained Virological Response November 26, 2019 February 28, 2024
NCT05368974 Unknown status The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry February 11, 2022 June 30, 2023
NCT02335320 Unknown status Qualification of Point-of-Care Assays for Management of HCV Patients March 2015 March 2016
NCT05372874 Unknown status Treatment of Hepatitis c by Using Direct-acting Antiviral May 6, 2022 July 30, 2022
NCT04242433 Unknown status HCV RAS Testing in Public Health Programs July 16, 2017 August 2021
NCT03359746 Unknown status Phase 4 Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant December 15, 2017 December 31, 2018
NCT02363517 Unknown status Phase 3 The TAP Study: Treating People Who Inject Drugs in Community-Based Settings Using a Social Network Approach February 2015 December 2019
NCT04244383 Unknown status Phase 4 Expression of Inflammasomes in HCV Patients January 2020 July 2020
NCT03362866 Unknown status Epidemiology of Hepatitis B, C and Delta in Reunion Island January 2019 April 2023
NCT03364725 Unknown status Phase 4 Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study January 15, 2018 March 1, 2019
NCT01274208 Unknown status Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C January 2011 April 2016
NCT02395198 Unknown status Epidemiology of Hepatitis C Virus Infection Among Opioid Substituted Patients August 2014 July 2017
NCT05390424 Unknown status N/A Screening for Hepatitis B, Hepatitis C and AIDS Viruses Using Dried Blood Spot June 2022 September 2023
NCT03402165 Unknown status Phase 4 Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C January 1, 2017 December 30, 2022
NCT03407703 Unknown status Hepatitis C (HCV) Cure and Kidney Health March 27, 2018 December 31, 2019
NCT02485262 Unknown status Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience November 2013 November 2016
NCT01315054 Unknown status N/A A Methadone Maintenance Treatment Outcome Study in Three Provinces in China May 2011 December 2014
NCT03418636 Unknown status N/A The Staying Safe Intervention January 31, 2018 May 31, 2021
NCT01327729 Unknown status Phase 2/Phase 3 Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C November 2010 May 2013
NCT03433326 Unknown status Grazoprevir and Elbasvir Without Ribavirin for 12 Weeks in Patients With HCV-related Cryoglobulinemic Nephropathy March 1, 2018 December 31, 2018
NCT00188240 Unknown status N/A Insulin Resistance Associated With Chronic Hepatitis C (CHC) and the Effect of Antiviral Therapy August 2003
NCT04395118 Withdrawn N/A STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention for Elevated LFTs August 15, 2020 January 1, 2022
NCT01654939 Withdrawn Phase 4 Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease October 2012 September 2015
NCT02551861 Withdrawn Phase 2 A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3 December 2015 June 2017
NCT01625793 Withdrawn N/A Inflammation, Stress & Social Behavior: Using Ecological Assessments & Model Systems to Enhance Relevance to Health Outcomes June 2012 July 2013
NCT00976781 Withdrawn Identifying the Gaps in the Diagnosis and Management of Hepatitis C August 2008 April 2009
NCT00951223 Withdrawn Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep C August 2009 April 2011
NCT03158857 Withdrawn Hepatitis C Treatment Study in Myanmar January 2022 January 2024
NCT02070107 Withdrawn N/A Technology-Based Application To Improve The Triple Therapy Adherence Rate In Subjects With Hepatitis C Infection April 2014 March 2016
NCT01430000 Withdrawn Phase 1/Phase 2 Safety and Efficacy of Sustained Interferon Alfa 2b (INF) Therapy of Relapsing Hepatitis C (HCV) Patients Using InfraDure Biopump
NCT03143998 Withdrawn Phase 4 Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4) February 12, 2018 January 12, 2019
NCT02762448 Withdrawn Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas July 2016 April 18, 2018
NCT00930995 Withdrawn Phase 2 Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C
NCT00167557 Withdrawn Phase 4 Orthotopic Liver Transplant (OLT) Recipients With Hepatitis C Virus (HCV) Under Preemptive Treatment January 2005 March 2008
NCT01949077 Withdrawn Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir. December 2011 January 2016
NCT03093740 Withdrawn Phase 4 Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant October 1, 2018 January 31, 2021
NCT02306070 Withdrawn Phase 2 Improving Fibrosis Outcomes With Metformin January 2016 April 3, 2018
NCT03208322 Withdrawn Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults November 30, 2018 February 27, 2019
NCT00547716 Withdrawn N/A Use of Omega-3 Fatty Acids (Fish Oil) in Patients With Chronic Hepatitis C Infection June 2009 August 2012
NCT01890772 Withdrawn Phase 2/Phase 3 Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1 August 2013
NCT00814606 Withdrawn Phase 2 A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C February 2010 October 2010
NCT03026023 Withdrawn Phase 4 Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant August 1, 2018 June 30, 2021
NCT00121017 Withdrawn Phase 2 A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects
NCT03313414 Withdrawn Phase 4 HCV Post-Exposure Prophylaxis for Health Care Workers August 13, 2019 January 16, 2020
NCT01025531 Withdrawn Cell Bound Complement Activation Proteins as Markers of Liver Injury December 2008 December 2014
NCT00165919 Withdrawn Immune Response to Hepatitis C Virus September 2005 September 2005
NCT00051077 Withdrawn Phase 2 Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)
NCT00023218 Withdrawn N/A Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis
NCT03585101 Withdrawn Phase 4 A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk August 2018 April 2020
NCT01797848 Withdrawn Phase 3 Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients June 2014 November 2016
NCT04309734 Withdrawn Phase 1/Phase 2 Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects October 2021 September 2022
NCT01549496 Withdrawn Phase 1 A Drug Interaction Study of Boceprevir in Combination With Amlodipine or Diltiazem in Healthy Volunteers May 2012
NCT01225705 Withdrawn Phase 4 Safety Study of Raltegravir in HIV/HCV Co-infected Patients October 2010 August 2012
NCT01415141 Withdrawn Phase 4 Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism July 2011 July 2011
NCT01770223 Withdrawn Phase 4 A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113) January 2014 December 2015
NCT00381017 Withdrawn Phase 3 Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371) September 2006
NCT02890719 Withdrawn Phase 3 Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients. May 2, 2017 December 2017
NCT03791814 Withdrawn Phase 4 A Prospective Cohort Study to Improve HCV Care in Dialysis Patients January 1, 2019 June 30, 2019
NCT02204475 Withdrawn Phase 3 Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066) November 2014 September 2016
NCT03623568 Withdrawn Phase 4 Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant February 15, 2019 April 15, 2021
NCT04320290 Withdrawn Phase 4 HCV + to HCV - Kidney Transplant May 21, 2020 June 16, 2020
NCT00371579 Withdrawn N/A Rosuvastatin for Hepatitis C October 2006 October 2007
NCT02556086 Withdrawn Phase 2 A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1) December 2015 July 2017
NCT00704756 Withdrawn An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN) January 2009 March 2010
NCT03702218 Withdrawn Early Phase 1 Hepatitis C Positive Donor Into Hepatitis C Negative Recipients July 1, 2019 July 1, 2019
NCT04546802 Withdrawn Phase 3 HepATocellular Cancer Hcv Therapy Study September 2019 June 2023
NCT00449124 Withdrawn Phase 1 TG4040 in Patients With Chronic HCV September 2007
NCT01157975 Withdrawn Phase 2 Study the Relationship Between Obesity and Hepatitis C Replication October 2008 September 2014
Disase is a (Disease Ontology)
DOID:934
Cross Reference ID (Disease Ontology)
EFO:0003047
Cross Reference ID (Disease Ontology)
ICD10CM:B19.20
Cross Reference ID (Disease Ontology)
ICD9CM:070.7
Cross Reference ID (Disease Ontology)
MESH:D006526
Cross Reference ID (Disease Ontology)
NCI:C3098
Cross Reference ID (Disease Ontology)
SNOMEDCT_US_2023_03_01:154349000
Cross Reference ID (Disease Ontology)
UMLS_CUI:C0019196
Exact Synonym (Disease Ontology)
chronic hepatitis C
Exact Synonym (Disease Ontology)
hepatitis C infection
Exact Synonym (Disease Ontology)
hepatitis nonA nonB
Exact Synonym (Disease Ontology)
NANBH
Exact Synonym (Disease Ontology)
Viral hepatitis C
MedGen concept unique identifier (MedGen Concept name)
C0019196
MedGen unique identifier (MedGen Concept name)
42425
MeSH unique ID (MeSH (Medical Subject Headings))
D006526